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ABSTRACT OF DISSERTATION

MECHANISMS OF CYCLOOXYGENASE-2-DEPENDENT HUMAN
AORTIC SMOOTH MUSCLE CELL PHENOTYPIC MODULATION
Abdominal aortic aneurysm (AAA) is a disease of the aorta characterized
by pathological remodeling and progressive weakening of the vessel resulting in
the increased risk of rupture and sudden death. In a mouse model of the disease
induced by chronic Angiotensin II (AngII) infusion, progression of AAAs is
associated with reduced differentiation of smooth muscle cells (SMCs) at the site
of lesion development. In the mouse model, the effectiveness of cyclooxygenase2 (COX-2) inhibition for attenuating AAA progression is associated with
maintenance of a differentiated SMC phenotype. However, the safety of COX-2
inhibitors is currently in question due to the increased risk of adverse
cardiovascular events. Thus, it is crucial to identify mediators downstream of
COX-2 that may provide new targets for treatment of this disease.
Recent studies in humans and mouse models have suggested that the
microsomal prostaglandin E synthase (mPGES-1) enzyme, which acts
downstream of COX-2, may also be involved in the pathogenesis of the disease.
We hypothesized that increased prostaglandin E2 (PGE2) synthesis resulting
from the induction of both COX-2 and mPGES-1 may result in reduced
differentiation of SMCs, and that disruption of this pathway would preserve the
differentiated phenotype. To test this hypothesis, human aortic smooth muscle
cells (hASMCs) were utilized to examine the effects of a variety of agents
involved in AAA development and the COX-2 pathway.
My findings suggest that one of the effects of exposing hASMCs to AngII
involves a specific induction of mPGES-1 expression. Furthermore, although
different COX-2-derived products may have opposing effects, mPGES-1-derived
PGE2 may be the primary prostanoid synthesized by SMCs which functions to
attenuate differentiation. Therefore, mPGES-1 inhibition may provide inhibition of

PGE2 that is more specific than COX-2 inhibitor treatment and may serve as a
therapeutic target for attenuating AAA progression by maintaining a differentiated
SMC phenotype.

KEYWORDS: vascular smooth muscle cell phenotype, abdominal aortic
aneurysm, Angiotensin II, prostaglandin E2, microsomal prostaglandin E synthase
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CHAPTER 1: INTRODUCTION
1.0 Physiology of mammalian blood vessels
During embryogenesis, blood vessels are among the first organs to
develop as these vessels are important for further organogenesis as well as for
sufficient nutrition of the embryo [1]. Mature blood vessels are comprised of three
distinct layers: the tunica intima, tunica media, and tunica adventitia. The tunica
intima is composed of endothelial cells lying on a basement membrane of type IV
collagen, laminin and heparin sulfate proteoglycans. Between the intima and the
media is a layer of internal elastic lamina composed of mainly elastin and
hyaluronic acid. The tunica media is primarily composed of elastic fibers and
smooth muscle cells (SMCs) arranged circumferentially. The adventitia, which is
the outermost layer, consists mainly of collagen fibers, loose connective tissue,
fibroblasts, and fat cells, with an external elastic lamina separating this layer from
the outer media [2].

1.1 Phenotypic modulation of VSMCs
The SMCs are responsible for maintaining artery wall tension via
contraction-relaxation, vascular remodeling, repair, as well as growth [2-6].
Normal smooth muscle cells have a distinct smooth appearance and the
differentiated phenotype is specifically marked by the expression of SMC lineage
markers and the acquisition of contractile function [7]. Cell differentiation involves
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transition from an initial multipotential state to a specialized form thus assuming a
different morphology as well as function [6].
Phenotypic modulation is a unique characteristic of vascular SMCs which
is demonstrated by their ability to switch their phenotype between the contractile
(differentiated) and synthetic (de-differentiated) phenotypes in response to
various environmental/external cues such as growth factors/inhibitors,
inflammatory mediators, cytokines, and matrix metalloproteinases [8-18]. This
characteristic property of vascular SMCs is important in regulation of vascular
function in health and disease [19]. The contractile and synthetic phenotypic
states are two extremes of the spectrum of SMC phenotypic expression and cells
expressing features of both phenotypes have been identified [20]. Furthermore,
vascular SMCs do not de-differentiate terminally but retain sufficient plasticity to
change back and forth between the differentiated and de-differentiated
phenotypes [21]. A variety of transcription factors including myocardin, myocardin
related transcription factors (MRTFs), and members of the Krüppel-like zinc
finger family (KLF) have been suggested to act as molecular switches involved in
the regulation of vascular SMC differentiation [22]. Increased binding of the
serum response factor (SRF) and its coactivator myocardin and then to the CArG
motif of differentiation marker genes, induces transcription and increased
expression of these differentiation markers [23].
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1.1.1 The contractile differentiated phenotype
The differentiated/contractile phenotype is demonstrated by expression of
several SMC contractile proteins that are used as differentiation markers (e.g.
smooth muscle α-actin, SMC myosin heavy chain, β-tropomyosin, desmin, hcaldesmon, calponin, smoothelin, and SM22α) which are involved in
maintenance and regulation of contractile function [7, 12, 24-29]. Cells in this
phenotype contract in response to chemical and mechanical stimuli and thus
function in regulating blood pressure and flow [26].

1.1.2 The synthetic de-differentiated phenotype
Cells in the de-differentiated or synthetic phenotype downregulate the
expression of differentiation markers and express high levels of synthetic
phenotype markers (e.g. hyaluronic acid, MMP-2, l-caldesmon, vimentin, and
non-muscle myosin heavy chain B). Furthermore, these de-differentiated cells
exhibit large, rhomboid, flattened, fibroblast-like morphology, and demonstrate an
increase in proliferative and migration rates compared with the contractile
phenotype [12, 15, 16, 26, 28, 30-34]. Previously, the proliferation and
differentiation processes were assumed to be coupled, with reduction in
differentiation being a prerequisite for proliferation. However, these processes
are now understood to be independent wherein growth factors may induce
proliferation independent of reduced differentiation marker expression and viceversa [35].
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1.2

Micro RNAs and the vascular SMC phenotype
Micro RNAs (miRs) are endogenous, small single-stranded, non-coding RNAs

about 22 nucleotides in length which base pair with the 3’-untranslated region
(UTR) of target RNAs thereby modulating gene expression and protein synthesis
[36, 37]. Depending on the degree of complementarity between a mature mRNA
and its target mRNA UTR, microRNAs may regulate gene expression by
mediating translational repression, activation or degradation of the target mRNA
[37]. In vascular SMCs, a variety of miRNAs have been reported to regulate the
phenotype of these cells in response to vascular injury thus indicating that
manipulation of these targets/mediators may be utilized as potential new
therapeutic targets [36].
Numerous reports have indicated that miR-145 which is the most abundant
miR in normal vascular walls, has been demonstrated to regulate the phenotype
of vascular SMCs. miR-145 is expressed in a gene cluster with miR-143 and
deficiency of this cluster in mice has been demonstrated to result in the reduced
abiity of miR-143/145-deficient mice to acquire the contractile phenotype due to
their accumulation of synthetic vascular SMCs and specific defects in GPCR
receptor-mediated signaling [38]. Overexpression of these miRs in a rat model of
acute vascular injury was demonstrated to decrease neointimal formation while
loss of this cluster resulted in altered differentiation of the SMCs and structural
modification of the aorta [39]. Furthermore, miR-145 has been identified as a
phenotypic marker for the differentiated phenotype in cultured vascular SMCs
and it also induces expression of vascular SMC differentiation marker genes [40].
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In addition, the miR143/145 cluster has been demonstrated to promote
differentiation and repress proliferation in vascular SMCs by inhibiting
suppressors of myocardin/serum response factor activity such as Kruppel-like
factor 4 (KL4), and ELK1 (member of ETS oncogene family) [22, 41].
Other miRs apart from the miR143/145 cluster have been involved in the
regulation of the vascular SMC phenotype. Recent research has identified miR663 as a novel regulator of phenotypic switch and function in human aortic
vascular SMCs. Overexpression of this miR promotes the contractile phenotype
and suppresses formation of neointimal lesions in a mouse model of vascular
injury by suppression of JUNB expression [42]. Furthermore, increased
expression of miR-21 induced by TGFβ and BMP signaling mediates the
induction of the contractile phenotype in vascular SMCs [43]. On the other hand,
miR-31 has been shown to bind to its target gene cellular repressor of E1Astimulated genes (CREG), thus negatively regulating vascular SMC phenotypic
modulation by repressing expression of SMC differentiation markers [44].
Similarly, miR-221 which is upregulated by PDGF, reduces the expression of
vascular SMC differentiation markers by inhibition of c-Kit, which is a positive
regulator of myocardin expression [36, 45].
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1.3

Phenotypic modulation of VSMCs in the development of vascular

disease
Modulation of the vascular SMC phenotype plays a key role in contribution
to vascular pathology. The pathogenesis of most cardiovascular diseases usually
involves dysfunction of the vascular smooth muscle cells of the tunica media.
Fully differentiated vascular SMCs proliferate extremely slowly while expressing
low levels of extracellular matrix proteins. However, these processes are
reversed and in fact accelerated during vessel remodeling following vessel injury
or atherogenesis [46]. In certain vascular disorders such as atherosclerosis [4749], restenosis due to vascular injury [9, 50-52], hypertension, and abdominal
aortic aneurysms, the decrease in protein and mRNA expression of SMC
differentiation markers has been observed within the vascular wall [46, 53]. Also,
increased expression of de-differentiation markers by SMCs has been associated
with these diseases [15, 31, 53-61].
In in vitro vascular SMC culture models, the synthetic phenotype shows
changes in SMC morphology from large, flattened, fibroblast-like morphology
with increased SMC proliferative and migration rates, as compared to the
elongated, spindle-shape in the contractile phenotype [12, 15, 16, 26, 28, 30-33]
[34]. The identification of novel pathways altered during the progression of
vascular SMC phenotype modulation is important in the identification of
mechanisms contributing to cardiovascular disease.
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1.3.1 Atherosclerosis
Atherosclerosis which has been recognized as the leading cause of death
in the developed world, is a common vascular disorder characterized by arterial
hardening due to deposition of lipids, cholesterol and other substances within the
arterial walls forming plaques [62]. Rupture of these plaques may result in
thrombus formation and vessel occlusion, thus resulting in a myriad of
cardiovascular diseases including coronary, cerebrovascular and peripheral
artery disease [63]. During progression of atherosclerosis, the resulting
endothelial dysfunction due to a combination of changes in shear stress, oxidized
LDL and inflammatory cytokines, results in the increased expression of
endothelial adhesion molecules and loss of endothelium-derived factors such as
prostacyclin and nitric oxide [33, 63-65]. Furthermore, inflammatory cells that
have infiltrated into the vessel wall release mediators including growth factors
and cytokines that produce SMC phenotypic changes from the contractile to the
synthetic state resulting in increased migratory ability and deposition of
extracellular matrix (ECM) [62]. As the SMCs migrate into the intima, they
release proinflammatory factors that contribute to atherosclerotic lesion formation
[19]. These atherosclerotic lesions are characterized by the accumulation of
layers of de-differentiated SMCs, as well as lipid-filled macrophages [25]. Thus,
alteration of the vascular SMC phenotype affects the ability of the lesion to
respond to different agonists [66]. Recently, Yu et al (2012) reported vascular
SMC phenotypic modulation with acceleration of atherogenesis in COX-2 deleted
hyperlipidemic ApoE-deficient mice. This was demonstrated by the loss of SMC
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α-actin and upregulation of vascular cell adhesion molecule-1 (VCAM-1) in the
leukocyte infiltrated lesions [67].

1.3.2 Restenosis due to vascular injury
De-differentiation of vascular SMCs is often observed in the vessel wall
during progression of restenosis following to vascular wall injury caused by
percutaneous transluminal coronary angioplasty [9, 50-52]. Restenosis is an
initial repair process induced following vessel wall injury that occurs in response
to endothelial denudation or direct vascular trauma produced by the intravascular
procedure [52]. These de-differentiated cells subsequently migrate into the
subintimal space and increase proliferation rates. The de-differentiated SMCs
also synthesize large amounts of extracellular matrix and form lesions which
contribute to the restenosis and subsequent failure of the vascular intervention
[52].

1.3.3 Abdominal aortic aneurysm (AAA)
Abdominal aortic aneurysm is a disease of the aorta demonstrated by
arterial enlargement with predisposition to rupture which is associated with a high
mortality rate [18, 24, 68]. Although AAA is an often asymptomatic progressive
disease, the aorta may continue to enlarge progressively over months or years
increasing the risk of rupture [18, 68]. Ruptured AAAs are the 13th leading cause
of death in the United States and the 10th leading cause of death in Caucasian
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men 65 – 74 years of age [18, 24, 69, 70]. The primary risk factors include male
gender, advanced age and smoking [24]. In AAAs, the tissue lesion site is
commonly characterized by elastin fragmentation, increased inflammation, and
SMC depletion [24, 69, 71]. In addition, during the progression of AAAs, there is
observable vascular SMC medial degeneration characterized by SMC apoptosis
and reduction in medial SMC density compared with normal aortas [72]. Ailawadi
et al (2009) reported reduced expression of the differentiation markers SM22α
and SMα-actin in aneurysmal tissue obtained from animal and human studies,
when compared with control aorta [53]. Furthermore, Jiao et al (2010) reported
the decrease in the levels of SM22α, SM α-actin, and desmin in the vessel media
during the development and progression of carotid artery aneurysms in rabbits
when compared with those from control rabbits [73]. Current research in our lab
using a mouse model of AAAs induced by chronic angiotensin II (AngII) infusion,
demonstrated that progression of AAAs is also associated with reduced
differentiation of SMCs in the abdominal aorta. However, the treatment of these
mice with celecoxib, an inhibitor of the inducible cyclooxygenase-2 (COX-2)
enzyme, was effective at attenuating AngII-induced AAA progression, and this
was associated with maintenance of a differentiated SMC phenotype in the aorta
[74, 75]. Even though the process of AAA formation and development involves
complex pathological processes, a key factor in development of AAAs is the
phenotypic modulation of vascular smooth muscle cells (VSMCs).
Currently, there are no pharmacological agents for treating AAAs leaving
surgery (open or endovascular repair) as the only option [70, 76]. Surgery to
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repair AAA however, is not without its associated risks of morbidity and mortality,
and thus, it is important to discover and develop effective non-surgical therapies
for prevention and treatment of this disease.

1.4

Prostanoids and cyclooxygenases
Prostanoids are a family of cyclopentane derivatives of polyunsaturated

fatty acids formed from arachidonic acid via the cyclooxygenase pathway and are
important mediators of allergic reactions and inflammation [26, 77]. The
cyclooxygenase (COX) enzymes catalyze the first step in the production of
prostanoids. Two isoforms of the COX enzyme exist: COX-1, which is the
constitutive enzyme, and COX-2, which is the inducible form. The amino acid
sequences for both isoforms have about 75% homology, and the catalytic
residues of these enzymes are highly conserved [78]. Both enzymes have
different subcellular localizations as well as different tissue expression profiles
with the COX-1 enzyme primarily associated with “housekeeping” functions in
normal tissues such as hemostatic, gastric protection, and renal water balance
[63, 79]. However, in response to stress, cytokines, growth factor stimulation, and
inflammatory stimuli, COX-2 which is extremely low in most normal tissues
(except in the kidney, testis, tracheal epithelium, and central nervous system)
expression is increased. Also, macrophages are a major source of
prostaglandins within the vessel wall. In addition, COX-2 expression is increased
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in certain pathological conditions such as tissue injury, malignant transformation
of gastrointestinal and mammary epithelium [79].
The COX enzymes convert arachidonic acid into prostaglandin G2 (PGG2)
via oxygenation, and then prostaglandin H2 (PGH2) which is synthesized from
PGG2 via peroxidase activity is subsequently converted by tissue specific
isomerases/synthases into different prostanoids including prostacyclin (PGI2),
prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), thromboxane (TXA2), and
prostaglandin F2α (PGF2α) [80, 81]. Different cells exhibit differential expression of
these synthases, thus determining the expression levels and production profiles
of individual prostanoids under basal as well as inflammatory conditions. The
cytoplasmic prostaglandin E2 synthase (cPGES), prostaglandin D2 synthase
(PGDS), prostaglandin F reductase, and thromboxane A2 synthase (TXAS) are
said to be preferentially coupled with COX-1, whereas the microsomal
prostaglandin E2 synthase (mPGES-1), and prostacyclin synthase (PGIS) are
often coupled and co-induced with COX-2 in response to acute and chronic
inflammatory stimuli [82]. These prostaglandins exert their effects through their
specific receptors, thus prostaglandin synthase inhibitors as well as receptor
antagonists have been explored as potential therapeutic agents in the
management of several diseases [26]. The role of various prostanoids in the
pathogenesis of cardiovascular diseases has been extensively reviewed by
Yuhki et al (2010) [83].
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1.4.1 Modulation of prostanoid activity
The biological actions of these prostanoids may be modulated at the level
of the cyclooxygenase enzymes, individual synthases or the prostanoid receptors
[84]. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX-1 and/or COX2, thus limiting the production of prostanoids and the resulting inflammation
produced by the action of these lipid mediators [82]. Deletion of COX-2 has been
shown to result in re-diversion of arachidonic acid from the prostanoid synthesis
pathway to increased synthesis of products of the 5-lipoxygenase pathway [67].
Furthermore, abnormal regulation of the COX-2 enzyme has been implicated in
the pathology of numerous diseases including cancer, fever, Alzheimer’s
disease, and cardiovascular diseases [85, 86].

1.4.2 Role of Prostanoids in vascular SMC phenotypic modulation
1.4.2.1

Prostacyclin (PGI2)

Prostacyclin (PGI2) was discovered in the 1970’s by John Vane and
colleagues and observed to relax arteries and inhibit platelet aggregation [87].
Several studies have indicated that a balance between prostacyclin and
thromboxane A2 (proaggregatory) contributes to maintaining the endothelial
integrity and thrombus formation and overall vascular homeostasis [64, 88]. PGI2
is a potent vasodilator, antithrombotic, and inhibitor of vascular SMC proliferation,
leukocyte adhesion and platelet aggregation, and contributes to protection and
maintenance of vascular homeostasis. PGI2 is the main prostaglandin product of
arachidonic acid metabolism in the endothelial cells and is primarily synthesized
12

by the action of COX-2 [33, 63, 65, 89]. PGI2 is not stored, but exerts its effects
locally and is converted rapidly non-enzymatically to its inactive metabolite, 6keto prostaglandin F1α (PG F1α) [89]. In certain cardiovascular disorders such
as atherosclerosis, myocardial infarction, thrombosis, and pulmonary
hypertension, reduced prostacyclin activity has been implicated [33].
PGI2 signaling
Prostacyclin activity is mediated via its tissue-specific (predominantly
platelets and vascular SMCs) G-protein coupled prostacyclin receptor (IP).
Activation of the IP receptor results in Gs (G-protein) coupling resulting in
activation of adenylate cyclase (AC), formation of cAMP, and subsequent
activation of PKA [33] [64]. PGI2 activation of the IP receptor has also been
reported to couple to Gq and mobilize Ca2+, whereas high concentrations of
prostacyclin agonists have been reported to preferentially activate PPAR-α or
PPAR-δ [64].
It has been previously reported that prostacyclin and prostacyclin analogs
induce differentiation in vascular SMC cultures [33, 52, 90]. Iloprost (prostacyclin
analog) has been shown to induce SMC-specific differentiation markers and
contractile morphology in cultured human vascular SMCs [33, 91, 92]. Recent
studies by Tsai et al (2009) demonstrated that PGI2 induces SMC contractile
phenotype, suggesting that a deficiency in PGI2 may result in SMC phenotypic
alteration to the synthetic state [19]. Furthermore, treatment of vascular SMCs in
the synthetic phenotype with varying concentrations of iloprost resulted in
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induction of expression of SMC differentiation markers such as SMα- actin, SM2MHC, h-caldesmon and SM-MHC via activation of the downstream
Gs/AC/cAMP/PKA pathway [33]. In addition, iloprost has been shown to induce
expression of COX-2, upregulation of 6-keto PGF1α, in addition to inducing
prostacyclin release in human vascular SMCs via independently-related
prostacylin signaling pathways (cAMP/PKA and ERK1/2 activation), and the
inhibition of Akt-1 signaling [92].
Similarly, PGI2 has been implicated in reducing rates of proliferation and
migration in VSMCs in vitro and in vivo [64]. Similar to COX-2 inhibition, defective
PGI2 signaling via the IP receptor has been shown to be associated with increase
adverse cardiovascular events [93]. Furthermore, Arehart et al (2008)
demonstrated that defective human IP receptor increased the rate of
atherothrombosis in patients attributable to decreased cAMP signaling in the
platelets and VSMCs, which may contribute to reduced ability to inhibit
thrombosis as well as VSMC proliferation and de-differentiation respectively [93].

1.4.2.2

Prostaglandin D2 (PGD2)

PGD2 is a prostaglandin which has been shown to inhibit platelet
aggregation and nitric oxide release, as well as act as an inductor of sleep and
vasodilation [94]. Though there is paucity of information regarding the effect of
PGD2 in modifying the phenotype of vSMCs, 15d-PGJ2 which is a stable naturally
occurring metabolite of PGD2 has been demonstrated to increase mRNA
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expression levels of differentiation markers, thus promoting smooth muscle cell
differentiation [95-99]. This effect of 15d-PGJ2 may be mediated via activation of
the peroxisome proliferator-activated receptor gamma (PPARγ) which is also
expressed in VSMCs [100-102]. Furthermore, treatment of cultured human
vascular SMCs with 15d-PGJ2 has been shown to promote differentiation [95-97].
PGD2 signaling
There exist two forms of PGD2 synthase, lipocalin-type (L-PGDS) and
hematopoietic-type (H-PGDS). L-PGDS is mainly responsible for PGD2 synthesis
[94]. Also, two receptors, DP1 and DP2, are associated with PGD2 signaling.
DP1 receptor activation due to ligand binding results in an increase in
intracellular cAMP while DP2 receptor activation inhibits cAMP synthesis and
increases intracellular calcium [82].

1.4.2.3

Thromboxane A2 (TXA2)

Thromboxane A2 (TXA2) is produced in platelets as well as in monocytes
and VSMCs, and is involved in promotion of platelet aggregation and
vasoconstriction [63, 77]. TXA2 has been shown to produce opposing actions to
PGI2 in that TXA2 is a potent vasoconstrictor and platelet activator working in
concert with PGI2 (vasodilator) to maintain vascular homeostasis [89]. An
imbalance in the existence of both prostanoids may contribute to cardiovascular
dysfunction observed in most vascular diseases [83].

15

TXA2 signaling
TPα and TPβ are the two isoforms of the TP receptor, activation of which
results in calcium ion mobilization [82] These TP isoforms may homodimerize
(e.g TPβ/ TPβ) or heterodimerize with each other (TPα/TPβ), or with the IP
receptor. The TP receptor may couple with Gq to activate PLC or with G13 to
activate RhoGEF thus promoting platelet activation, aggregation and
vasoconstriction [63].

1.4.2.4

Prostaglandin F2α (PGF2α)

PGF2α is formed from the reduction of PGH2 due to the action of the PGF
endoperoxide reductase/synthase (PGFS). However, this prostanoid may also be
formed from PGE2 through 9-keto reductases or from PGD2 through 11-keto
reductases [84]. Two forms of PGFS have been identified, PGFS-1 and PGFS-2,
and two human splice variants of the FP (FPA, FPB) exist [82]. Activation of the
FP receptor has been reported to trigger Gq protein signaling which may be
linked to cellular proliferation or activation of Rho and may result in changes in
cell cytoskeleton and morphology [84].

1.4.2.5

Prostaglandin E1 (PGE1)

PGE1 has been shown to induce and increase proliferation as well as the rate of
phenotypic modulation of rat aortic SMCs from the contractile to the synthetic
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state early in primary culture. However, later on in the culture, PGE1 inhibited
DNA synthesis and cellular proliferation [77].

1.4.2.6

Prostaglandin E2 (PGE2)

PGE2 is the principal prostanoid secreted during inflammation and is
involved in production of proinflammatory cytokines resulting in alteration of
vascular SMC contractile function, increased vascular permeability, dilation and
pain [4, 52, 85, 103-105]. In addition, PGE2 has been reported to play a key role
in epithelial physiology especially in gastrointestinal tissues [79]. PGE2 is
synthesized by the action of the Prostaglandin E2 synthase (PGES) enzyme
which exists in 3 isoforms: cytosolic (c-PGES), type 1 membrane-associated
(mPGES-1) and type-2 membrane associated (mPGES-2) [106, 107]. cPGES
and mPGES-2 are expressed constitutively, with cPGES coupling predominantly
with the constitutive COX-1 enzyme while mPGES-2 couples with both COX-1
and COX-2 [85, 105, 108, 109]. cPGES is a cytosolic protein constitutively
expressed in a variety of tissues and is generally resistant to stimulation by
proinflammatory stimuli [110, 111]. mPGES-2 is mainly expressed in the heart
and brain, however, its biological function is not well described [111]. mPGES-1,
(also known as microsomal prostaglandin E2 synthase) belongs to the MAPEG
(membrane-associated proteins involved in eicosanoid and glutathione
metabolism) superfamily [112]. This is the inducible isoform which is associated
with the perinuclear membrane, and is generally found to be co-expressed and
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functionally coupled with COX-2 in response to a range of extracellular and
intracellular stimuli and downregulated by anti-inflammatory glucocorticoids [17,
85, 106, 108, 111, 113-120]. In addition, in most cells, the most prominent PG
produced during the delayed response is PGE2 associated with COX-2
expression, and COX-2 inhibitors reduce PGE2 production more profoundly than
the other prostanoids [85]. The majority of the PGE2 formed in response to COX2 induction is dependent on mPGES-1 [121-123]. Recent research has also
demonstrated that PGE2 can also increase COX-2 expression. For example,
PGE2 has been found to increase COX-2 and cPLA2 expression through
activation of MAPK and NFκB pathways [124, 125]. In contrast however,
Chandrasekharan et al (2005) reported that PGE2 production in the murine
mammary gland depends on functional coupling of the COX-1 enzyme with
mPGES-1[79].
PGE2 signaling
PGE2 activity is modulated via activation of its G-protein-coupled
receptors: EP1, EP2, EP3 and EP4 which are structurally and functionally distinct
[105, 126]. These receptors have unique tissue expression profiles and their
effects are mediated through different downstream signaling pathways [79, 127129]. EP2 and EP4 are coupled to Gs and activation of these receptors cause
increases in intracellular cAMP levels. Furthermore, EP4 signaling pathway may
involve phosphatidyl inositol 3-kinase (PI3K), resulting in protein kinase B (Akt)
and extracellular signal-related kinases (ERK) activation [83]. The EP3 receptor
which has 8 different splice variants is coupled to both G1 and Gq; and activation
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may result in increased intracellular Ca2+ levels, reduce, or increase cAMP
production depending on the expression of the EP3 splice variant(s) in the cell
[79, 82].
In vascular SMCs, the effects of PGE2 in regulating differentiation will
depend on the EP receptor(s) expressed in the cell type. Studies have shown
differential expression of the different EP receptors in various disease states and
cell culture models [5, 104, 130, 131]. For example, a variety of the EP receptors
including EP2, EP3, and EP4 have been shown to be expressed in cultured
SMCs obtained from AAA tissues, however only EP2 and EP3 receptors were
found in cultured human aortic smooth muscle cells [126]. Expression of these
receptors has also been shown to be dependent on vascular SMC culture
conditions, with EP4 showing greatest expression and EP1 and EP2 being
undetectable under growth-promoting conditions [132]. EP4 receptor protein has
been shown to be present in AAA lesions of both mice and human samples and
inhibition of this receptor in mice results in reduction of the incidence and severity
of AAAs [133, 134].
PGE2 has been demonstrated to alter actin organization in cultured rat
vascular SMCs, which may indicate an effect on de-differentiation [104]. In
addition, hyaluronan synthase and MMP activity, which are characteristics of the
de-differentiated phenotype, have been shown to be stimulated by PGE2 in
several cell culture and vascular disease models [34, 135-141]. In other cell
types, EP receptor expression has been shown to change under different states
of differentiation. In chondrocytic cells for example, increased COX-2 expression
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was shown to correlate with increased expression of EP2 and EP3a1 mRNA,
whereas no change was observed with the EP1 and EP4 receptors [142]. In
addition, reduced differentiation of renal glomerular cells induced by PGE2 was
suggested to occur via EP4 upregulation and activation [143]. Furthermore,
expression of EP4 in the ductus arteriosus, has been shown to increase with
advancing gestational age [144, 145]. Thus, these reports suggest that there are
changes in EP receptor expression under different states of cell differentiation.
Even though individual prostanoids and their analogs demonstrate a high
degree of cognate receptor selectivity, the level of specificity depends on the
ligand concentration, as prostaglandin analogues selective for one receptor at a
given concentration may lose selectivity at higher concentrations and exhibit
cross-reactivity with multiple prostanoid receptors [146]. The potential for
nonselective effects of prostanoids or analogues increases the complexity of
identifying novel functions of these mediators. The complexity of analysis is
further enhanced given that prostanoid action involves the enzymatic activity of
phospholipases, cyclooxygenases, and prostanoid synthases, together with
specific receptors activating unique intracellular events. Therefore, the complete
characterization of a prostanoid-dependent biological response may require the
understanding of coordinated processes involving numerous enzymatic and
signaling pathways.

Copyright © Oreoluwa O. Adedoyin 2014
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CHAPTER 2: HYPOTHESIS AND SPECIFIC AIMS
Abdominal aortic aneurysm (AAA) is a cardiovascular disease affecting 1 in
every 10 adults over 55 years of age. Ruptured AAAs are the 13th leading cause
of death in the United States and the 10th leading cause of death in Caucasian
men 65 – 74 years of age in the United States. It is characterized by progressive
dilation of the aorta within the abdominal region which may result in rupture and
sudden death if left. Unfortunately, there are no medications approved for the
prevention or treatment of this disease leaving surgery is the only option. Surgery
to repair AAA however, is associated with significant risk of morbidity and
mortality, and is therefore reserved for the most severe cases of the disease. For
patients with smaller aneurysms who do not qualify for surgical repair however,
the medical approach recommended is “watchful waiting” [18, 24, 69, 70, 76].
Recent findings have demonstrated that during the development of this
disease, one of the characteristics observed during the pathological remodeling
observed within the aorta is the alteration of the differentiation state of the
vascular smooth muscle cells (SMCs) within the aneurysmal lesion. The cells in
the contractile differentiated state undergo a process of de-differentiation into the
synthetic de-differentiated state which is characterized by a loss in the
expression of differentiation markers and increase expression of markers of the
synthetic phenotype. In human biopsies obtained from patients undergoing
aneurysmal repair, Ailawadi et al observed increased expression of markers of
the de-differentiated phenotype and decreased expression of markers of the
differentiated phenotype compared with normal aorta [53]. Furthermore, using a
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mouse model of AAAs induced by chronic angiotensin II (AngII), the progression
of AAAs has been shown to be associated with reduced differentiation of SMCs
in the abdominal aorta. The treatment of these mice with celecoxib, an inhibitor of
the inducible cyclooxygenase-2 (COX-2) enzyme, was effective at attenuating
AngII-induced AAA progression, and this was associated with maintenance of a
differentiated SMC phenotype in the aorta [74]. These findings suggest that
COX-2 may play a role in altering the differentiation state of SMCs within the
aorta during development of this disease.
Together with COX-2, other components of the prostanoid synthesis pathway
have been implicated in the pathogenesis of AAA. In aneurysmal tissue, the
increased expression of COX-2 and microsomal prostaglandin E synthase-1
(mPGES-1), and the increased synthesis of prostaglandin E2 (PGE2) have been
observed, as compared to uninvolved aorta [71, 126, 147-151]. Genetic
inactivation or pharmacological inhibition of COX-2 in mouse AAA models
significantly reduces AAA incidence and severity compared with wild-type mice
[71, 148]. Even at the site of ruptured AAAs in humans, the COX-2 gene was
found to be overexpressed in aneurysmal lesions compared to normal aortic
tissues [151]. Wang et al (2008) demonstrated that deletion of mPGES-1 (an
enzyme that acts downstream of COX-2) in AngII-induced AAA mouse models
significantly attenuated the incidence and severity of AAAs [128]. Similarly,
pharmacological or genetic inhibition of the prostaglandin E subtype 4 receptor
(EP4) also attenuates the incidence and severity of AAAs in both human and
mouse models of this disease [133, 134]. Despite these promising findings
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however, because certain COX-2 inhibitors have been associated with increased
risk of adverse side effects in humans, COX-2 inhibitors have not been approved
for treatment of this disease in patients. It is therefore important to identify
mediators downstream of this enzyme which will provide new targets for the
treatment of this disease.
With previous findings of the effectiveness of COX-2 inhibition in attenuating
the development and progression of AAAs in a mouse model being associated
with maintenance of a differentiated SMC phenotype, the primary objective of the
current research is to identify mechanisms by which COX-2 affects SMC
differentiation using an in vitro cell culture model of human aortic smooth muscle
cells (hASMCs). In order to examine this, the following hypothesis was proposed
: Increased prostaglandin E2 (PGE2) synthesis in the hASMCs due to the
induction of COX-2 and mPGES-1 may result in reduced differentiation of SMCs,
and that disruption of this pathway would preserve the differentiated phenotype.
hASMCs were utilized to assess the role of COX-2 and mPGES-1-dependent
production of prostaglandin E2 (PGE2) in contributing to reduced SMC
differentiation. This project has 3 specific aims:

(1) Examine the role of COX-2 in hASMC phenotypic modulation
a. Correlate COX-2 levels with changes in the hASMC phenotype in vitro
b. Investigate the effect of pharmacological inhibition of COX-2 on the hASMC
phenotype
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(2) Investigate the importance of AngII in hASMC phenotypic modulation
a. Examine the effect of AngII treatment on the hASMC differentiation state
b. Correlate AngII-induced phenotypic changes with the expression of COX-2
and mPGES-1

(3) Determine the role of PGE2 synthesis by COX-2 and mPGES-1 in the
induction of hASMC de-differentiation
a. Examine the effect of exogenous PGE2 treatment on hASMC phenotypic
modulation.
b. Determine the effect of pharmacological inhibition of mPGES-1 on preventing
hASMC de-differentiation
c. Using siRNA mediated knock-down of mPGES-1, determine the effect of
reduced mPGES-1 expression and PGE2 synthesis on preventing dedifferentiation

A better understanding of the role of the COX-2/mPGES-1/PGE2 pathway in
hASMC de-differentiation will be an important step forward in the discovery and
development of therapeutics for manipulation of the SMC phenotype, where
altered SMC differentiation may be a significant contributor to disease
progression.

Copyright © Oreoluwa O. Adedoyin 2014
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CHAPTER 3: MATERIALS AND METHODS
3.1

Cell culture
Human aortic smooth muscle cells (hASMCs) were purchased from

Cascade Biologics (Invitrogen) and cultured according to manufacturer
instructions using recommended media (Medium 231) with supplements to
induce either growth or differentiation. The basal culture medium used (Medium
231) was made up of essential and non-essential amino acids, vitamins, other
organic compounds, trace minerals, and inorganic salts [152]. Growth promoting
media was supplemented with 4.9% fetal bovine serum (FBS), heparin (5 ng/ml),
human basic fibroblast and epidermal growth factors (2 ng/ml and 0.5 ng/ml
respectively), and recombinant human insulin-like growth factor (2 µg/ml).
Differentiation-promoting media was made up of Medium 231 supplemented with
1% FBS, and heparin (30 µg/ml). Both growth-promoting and differentiationpromoting media also contained 1% penicillin and streptomycin. Cells used in all
experiments were from passages 2 – 8 and were cultured in a humidified 5%
CO2 atmosphere at 37oC. Cells were cultured under either growth-promoting
conditions with growth-promoting media, or under differentiation-promoting
conditions with differentiation-promoting media. Varying concentrations of drugs
or prostanoid receptor agonists/antagonists were used to treat cells prior to lysis
and harvest after specific time periods.
In order to induce differentiation in cells cultured under growth-promoting
conditions, the cell media was replaced with serum-deprived media and
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maintained under these conditions over time. In order to induce expression of
COX-2, or mPGES-1, growing cells were serum-starved overnight and then restimulated with serum-containing growth-promoting media.

3.1

Cell lysis and protein collection
After cell culture and treatment, cell culture media were either collected for

further analyses or discarded at pre-determined time points and adherent cells
were rinsed briefly two times with 1XPBS. Cells were lysed with equal volumes of
RIPA lysis buffer made up of 200 mM Tris with pH 7.6, glycerol, 10% SDS, 10%
deoxycholate, Triton X-100, 200 mM EDTA containing protease and
phosphatase inhibitors (PMSF and leupeptin). Cells lysates were subsequently
scraped and pipetted into 1.5 ml Eppendorf tubes for storage at -20oC until
further use.
Prior to protein separation via SDS PAGE, protein content in each sample
was analyzed using the Bicinchoninic Acid (BCA) method and specific volumes
corresponding to equal amounts of protein was added to fixed volumes of loading
buffer and heated at 100oC for 10 minutes. The loading buffer was made up of
0.5 M Tris (pH 6.8), glycerol, 10% SDS, 0.5% bromophenol and 5% βmercaptoethanol. After heating, the tubes were vortexed briefly, spun-down using
a microcentrifuge and then loaded unto polyacrylamide gels for protein
separation via western blotting.
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3.3

Western Blot Analysis
Equal amounts of cell lysates were loaded unto 12% polyacrylamide gels,

separated via SDS-PAGE and transferred unto nitrocellulose membranes (GE
Healthcare). Membranes were blocked for 1 hour with 5% bovine serum albumin
in Tris-buffered saline containing 1% Tween 20. Blots were then incubated
overnight at 4oC with specific primary antibodies. Antibodies against SMα-actin
(Sigma Aldrich), and SM22α (Abcam Inc.), were used as markers of
differentiation while de-differentiation was measured by a corresponding
decrease in these protein markers. Either α-tubulin (Cell signaling) or calnexin
(Cell signaling) were used as loading controls. Monoclonal α-actin primary
antibody was fluorophore conjugated with Cy3, while biotinylated anti-rabbit
secondary antibodies together with fluorophore-conjugated streptavidin
complexes were used for detection of SM22α, α-tubulin and calnexin. For COX-2
(Vector laboratories) and mPGES-1 (Oxford biomedical research) detection,
horse-radish peroxidase (HRP)-conjugated anti-rabbit IgG were used as
secondary antibodies. Protein detection of fluorophore-conjugated antibodies
was done via fluorescence imaging using the Typhoon laser scanner (GE
Healthcare), while HRP-conjugated antibodies were detected by enhanced
chemiluminescence. Images were analyzed and quantified via densitometry
using the Imagequant analysis software (GE Healthcare).
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3.4

mRNA isolation
mRNA was isolated from the hASMCs using the RNeasy kit (Qiagen Inc.,

CA, USA) according to manufacturer’s instructions. The procedure combines
selective binding properties of a silica-based membrane with the speed of
microspin technology [153]. Briefly, cultured cells were lysed and homogenized
with QIAshredder spin columns in the presence of a highly denaturing guanidinethiocyanate-containing buffer which inactivates RNases, thus ensuring
purification of intact RNA. Next, one volume of 70% ethanol was added to the
homogenized lysate, thus providing appropriate binding conditions and then
transferred to an RNeasy spin columns thus ensuring that total RNA binds to the
membrane and contaminants are washed away. Subsequent washes of the spin
columns with RNase-free water yielded high quality RNA elutes for further
analysis.

3.5

cDNA preparation via reverse transcription
Total RNA was reverse transcribed in a two-step process adapted from an

InvitrogenTM protocol [154]. The first step consisted of adding mRNA to a mix
containing random hexamers (1: 60 dilution), deoxynucleotide triphosphate mix
(dNTPs), and DEPC water in Eppendorf tubes. This mixture was heated for 5
minutes at 65oC on a thermal cycler (Eppendorf). To this was added a second
mix consisting of 5X reverse transcription buffer, 0.1 M DTT (dithiothreitol),
RNAse inhibitor, and Superscript II reverse transcriptase. Eppendorf tubes
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containing the final mixture were placed back on the thermal cycler and then
heated at 25°C for 10 minutes and then increased to 42°C for 50 minutes. After
these heating cycles, the reaction was terminated by heating at 70°C for 15
minutes and the tubes were stored at -20°C prior to being used for gene
expression analysis.

3.6

Quantitation of gene expression via RT-PCR
mRNA expression and quantitation of gene expression was performed via

the two-step Real-Time Polymerase Chain Reaction (RT-PCR) procedure. Here,
the PCR step using Superscript II (Invitrogen) was coupled with fluorogenic 5’
nuclease chemistry (Taqman) using primer/probe assays for smooth muscle αactin, SM22α, COX-2, microsomal PGE2 synthase (mPGES-1), matrix
metalloproteinase -2 (MMP-2), smoothelin, myosin heavy chain 2 (MyhII), and
hyaluronan synthase 2 (Has2) (Applied Biosystems (Foster City, CA). mRNA
expression of the constitutively expressed housekeeping gene hypoxanthine
phospho-ribosyl transferase (HPRT) was quantitated as an internal normalizing
control gene. Relative gene expression levels were calculated by comparing
cycle times for each target PCR using the the ∆∆ct method. To do this, the target
PCR Ct values were normalized by subtracting the HPRT Ct value, to give the
∆Ct value. The relative expression levels between treatments were then
calculated using the equation: relative gene expression = 2−(∆Ctsample-∆Ctcontrol)
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3.7

PGE2 Enzyme Immunoassay
PGE2 concentrations in cell culture media were determined using a PGE2

enzyme immunoassay (EIA) monoclonal kit according to the manufacturer’s
protocol (Cayman chemical company). This is a competitive assay between the
PGE2 present in the cell culture media and a PGE2-acetylcholinesterase
conjugate (PGE2 tracer) for a limited amount of PGE2 monoclonal antibody [155].
The wells in the plate are pre-coated with goat polyclonal anti-mouse IgG and
blocked with a proprietary formulation of proteins. Each well is incubated with a
fixed amount of the PGE2 tracer, cell culture media containing free PGE2 and
specific PGE2 monocolonal antibody for approximately 18 hours and stored at
4oC. Since the amount of PGE2 in the media varies, the amount of PGE2 tracer
that is able to bind to the PGE2 monoclonal antibody will be inversely proportional
to the concentration of PGE2 in the well. The antibody-tracer complex binds to
the goat polyclonal anti-mouse IgG used to pre-coat the wells. After incubation,
the mixture is discarded from the wells and after a series of wash steps, Ellman’s
reagent which contains a substrate to the acetycholinesterase is added to the
wells and the plate is placed on an orbital shaker and kept in the dark for 75
minutes to develop. An enzymatic reaction occurs between the
acetylcholinesterase and the substrate producing a yellow color which absorbs
strongly at 412 nm. The absorbance of the solution based on the intensity of this
color is determined spectrophotometrically using a plate reader set to 405 nm.
The amount of free PGE2 present in the well is inversely proportional to the
amount of PGE2 tracer bound to the well during the incubation.
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3.8

Immunocytochemistry
hASMCs were plated onto 12 or 24 well plates, fixed with 4%

paraformaldehyde and permeablized with 0.5% Triton X-100. After blocking with
1% bovine serum albumin (BSA) for 1 hour, cells were incubated overnight in
either Cy3-conjgated primary antibody for SMα-actin-Cy3 antibody (in 1%BSA) at
4oC. Alternatively other primary antibodies were detected with Cy3-conjugated
secondary antibodies. Cell nuclei were visualized with SYBR green (AB systems)
after incubation for 45 minutes at room temperature. Cells were washed with
1XPBS and plates were scanned and images were captured by the GE
Healthcare Typhoon fluorescence imager after each incubation. Using the
ImageJ analytical software, quantitation of fluorescent intensity/densitometry was
obtained and the ratio of α-actin to SYBR green was expressed as the extent of
differentiation observed in these cells.

3.9

mPGES-1 RNA interference via siRNA transfection
hASMCs were transfected with mPGES-1 siRNA using the

Lipofectamine® RNAiMAX transfection reagent (Invitrogen, NY USA), and
following the reverse transfection protocol as outlined by the company. 82.5 nM
of predesigned annealed siRNA targeted to mPGES-1 (siRNA ID 15540, Life
Technologies) and 3 uL of transfection agent were pre-plated onto empty 12 well
plates and then cell suspension in growth media was added to the wells. After
two days, the growth media was replaced with serum-free media for either 1 or 2
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days, and cell media was collected for PGE2 EIA analysis. Both protein and
mRNA samples were isolated from replicate treatments of these cells and
analyzed for phenotypic changes via western blotting or real time PCR
respectively.

3.10

Statistical analyses
Each experiment was repeated at least three times and statistical

analyses were carried out using the GraphPad Prism software version 5.04
(GraphPad Software Inc., San Diego, CA Prism 5.04). The mean and SEM were
calculated for each parameter with a single treatment considered as n of 1.
hASMC phenotype comparisons between differentiated and de-differentiated
cells were analyzed by two-way repeated measures ANOVA. Bonferroni post
tests were used where indicated. To compare the significance of the difference
between 3 or more treatment groups, one-way ANOVA test, followed by the
Dunnett’s multiple comparison post-hoc tests was utilized. Unpaired Student’s t
test was used to compare the effects observed between two groups. Statistical
significance was defined as P < 0.05.
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CHAPTER 4: CHARACTERIZATION OF THE HUMAN AORTIC SMOOTH
MUSCLE CELL PHENOTYPE
Introduction
Phenotypic modulation is a unique characteristic of vascular SMCs
demonstrated by their ability to switch their phenotype between the contractile or
differentiated phenotype to the synthetic or de-differentiated phenotype in
response to various external cues such as growth factors, inflammatory
mediators, and cytokines [8-18]. These cells do not differentiate terminally but
retain sufficient plasticity to switch back and forth along a continuum between the
differentiated and de-differentiated phenotypes. This unique characteristic of
vascular SMCs in phenotypic modulation is important in the regulation of
vascular function in health and disease. Both phenotypic states are simply two
extremes of the spectrum of vascular SMC phenotypic expression since cells
expressing features of both phenotypes do exist [19-21].
The principal function of vascular SMCs within the vasculature is
contraction, and this is mediated by the action of contractile proteins which are
expressed at increased levels in mature differentiated SMCs. The action of SMC
contraction and relaxation results in the alteration of the luminal diameter of the
blood vessels and contributes to the regulation of blood pressure and blood flow
[12, 46, 52]. Normal mature vascular SMCs exist in a quiescent non-proliferative
state and demonstrate a well-differentiated contractile phenotype. Cells in this
differentiated phenotype express greater levels of SMC contractile proteins such
as smooth muscle α-actin, SM22α, SM myosin heavy chain, and smoothelin
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compared with cells in the synthetic phenotype [7, 12, 24-29]. Furthermore, cells
in the contractile phenotype proliferate slowly while expressing low levels of
extracellular matrix proteins. On the contrary, cells in the de-differentiated
phenotype express increased levels of synthetic markers such as hyaluronan
synthase, collagens, and matrix-metalloproteinases, and have increased
proliferation and migration rates [12, 16, 26, 28, 30-34].
Alteration of the differentiated vascular SMC phenotype plays a key role in
contributing to vascular pathology. In certain vascular disorders such as
atherosclerosis, restenosis following vascular injury, hypertension, and
abdominal aortic aneurysms, a decrease in protein and mRNA expression of
SMC differentiation markers has been observed. This results in a change from
the differentiated to the de-differentiated phenotype within the SMCs of the
affected regions within the vascular wall. An important characteristic of this
change from the differentiated to the de-differentiated phenotype involves the
increased synthesis of extracellular matrix components, such as collagen,
hyaluronic acid and elastin [9, 30, 46-53]. The de-differentiation process, is also
associated with the re-entry of the SMCs into the cell cycle which is accompanied
by increased proliferation and migration rates [52]. This phenotypic shift to a lessdifferentiated phenotype, characterized by the reduction in differentiation markers
and increase in markers of the synthetic phenotype may be a crucial component
of the repair process [46]. When the vascular injury is resolved, the
environmental cues within the vessel change, causing the SMCs to reacquire
their normal contractile phenotype [9].

34

The addition of heparin to cell culture media and/or reduction of serum
concentration are methods that have been shown to induce and maintain
differentiation in smooth muscle cells. Heparin is a natural glycosaminoglycan
demonstrated to possess potent anti-proliferative and anti-migratory activity in
vascular smooth muscle cell in vitro and in vivo [156, 157]. Various molecular
mechanisms have been proposed for these actions in vascular SMCs. Heparin
has been shown to induce cell cycle arrest [158, 159], inhibit production of matrix
degrading enzymes [156, 160], regulate expression of extracellular matrix
proteins [161] induce growth-arrest specific genes [162, 163] and to inhibit the
activation of mitogen-activated genes [164]. In addition, heparin has been shown
to also promote the contractile phenotype in vascular SMCs by increasing
differentiation marker expression [165-168]. This characteristic of heparin has
been demonstrated to be mediated in part by the increase in TGFβ secretion, a
factor known to enhance the differentiation of SMCs [9, 169-171].
In addition to induction of vascular SMC differentiation by heparin, the
complete removal of serum albumin (serum deprivation) from cell culture media
has been demonstrated to promote the differentiated phenotype in vascular
SMCs [23, 44, 172, 173]. When SMCs are cultured under serum-free conditions
over time, these cells are induced to differentiate with acquisition of the requisite
morphology, contractile ability and increased expression of SMC differentiation
markers at comparable levels to that of differentiated cells [23]. However, this
induction of differentiation has been shown to be reversed upon administration of
growth factors, or serum-containing media [172, 174].
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Although a variety of different growth factors have been shown to induce
the synthetic phenotype, the identification of factors responsible for inducing the
contractile phenotype has been limited. One such endogenous factor that has
been proposed to maintain a differentiated phenotype under conditions of serumdeprivation is the cellular repressor of E1A-stimulated genes (CREG). CREG is
upregulated under conditions of serum-deprivation and has been shown to
promote differentiation by increasing expression of contractile markers, inhibiting
cell proliferation, and inhibiting the synthetic phenotype of vascular SMCs under
these conditions [175].
In contrast to agents that promote differentiation, the presence of a variety
of growth factors, and/or increased serum concentrations in the cell culture
medium have been demonstrated to promote cell proliferation, migration, and
phenotypic modulation from the contractile to the synthetic state in vascular
SMCs [6, 166, 167, 174, 176, 177]. Peyton et al (2002) demonstrated that
increased serum (10%) promotes vascular SMC proliferation by the induction of
heme oxygenase (HO-1) mRNA and protein expression. This serum-induced
increase in DNA synthesis was observed both in the presence and absence of
growth factors [178]. Similarly, increased serum and/or growth factor stimulation
in vascular SMCs have been observed to promote synthesis of proteoglycans
thereby promoting the synthetic SMC phenotype [179]. Furthermore, plateletderived growth factor (PDGF) has been shown to destabilize the cytosolic α-actin
mRNA pool at the transcriptional level resulting in significant reduction in actin
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mRNA and protein, thus promoting the de-differentiated SMC phenotype [180,
181].
To characterize the phenotype of our in vitro cell culture model, human
aortic smooth muscle cells (hASMCs) were cultured under different media
conditions and the effect of culture media on the SMC phenotype was examined
by measuring mRNA expression and protein levels of different markers of both
the contractile and synthetic phenotypes.

Results
4.1 Induction of phenotypic modulation by cell culture media
4.1.1 α-actin and SM22α are expressed at greater levels in the differentiated
phenotype compared with the de-differentiated phenotype
To induce differentiation in hASMCs, cells were cultured in differentiationpromoting media while de-differentiation-promoting media was used to promote
the synthetic phenotype. Compared to media promoting the de-differentiated
phenotype, differentiation-promoting media was made up of increased amounts
of heparin (6000-fold) and reduced amounts of fetal bovine serum (1%). On the
other hand, de-differentiation-promoting media contained increased serum (5fold), reduced heparin, and a variety of growth factors.
Cells were cultured under both conditions over time and after each time
point, cells were lysed and then either harvested for analysis via western blotting
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or alternatively, mRNA was collected for real-time PCR analysis. Significant
increase in α-actin and SM22α were used as the major markers of differentiation.
The level of α-actin expression was compared between differentiated (DC)
and de-differentiated conditions (d-DC) at each individual time-point. Significantly
increased α-actin mRNA expression was observed in cells cultured under
differentiation-promoting conditions compared with cells cultured under dedifferentiation-promoting conditions at each time point (Figure 4.1A). This finding
was also observed in the protein levels of α-actin with significantly greater levels
observed in cells cultured under differentiation-promoting conditions compared
with cells cultured under conditions promoting de-differentiation. In addition, over
the 5-day time period there was a significant increase in α-actin protein levels in
cells cultured under conditions promoting differentiation but this was not
observed under de-differentiation promoting conditions (Figure 4.1B). With
SM22α, significantly increased protein levels was observed in cells cultured
under differentiation promoting conditions but this increase ceased to be
significant beyond the 3rd day (Figure 4.1C).
In addition, even though protein levels of both α-actin and SM22α were
significantly increased under conditions promoting differentiation compared with
growth, there was greater increase in the expression levels of α-actin compared
with SM22α. There was a 12-fold increase in α-actin levels at the 5 day timepoint when compared with 1 day in cells cultured under differentiation-promoting
conditions. For SM22α however, the increase observed was only 5-fold.
Furthermore, the fold increase in protein levels when comparing cells in
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differentiation media to growth at every time point was greater with α-actin than
SM22α (Figure 4.1.1B & C).
Figure 4.1.1 α-actin and SM22α are expressed at greater levels in the
differentiated phenotype compared with the de-differentiated phenotype
(A) mRNA expression of α-actin in hASMCs cultured for 1 to 4 days under
conditions promoting differentiation or growth. Densitometry and representative
western blot showing protein levels of (B) α-actin and (C) SM22α, in hASMCs
cultured for 1 to 5 days under conditions promoting differentiation (DC) or dedifferentiation (d-DC). Data represents mean + SEM (n≥3), * = p < 0.05, ** = p <
0.01, *** = p < 0.001, and **** = p < 0.0001; two-way ANOVA used to determine
differences due to culture media and time. Bonferroni multiple comparisons
examining α-actin expression due to culture media were conducted within each
time point. α- actin expression after 1 day in differentiation-promoting media was
used as control.
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was isolated and analyzed for HAS2 expression via real time PCR. An increase
in HAS2 was used to indicate de-differentiation in these cells.
In contrast to α-actin and SM22α expression patterns, cells cultured under
differentiation-promoting conditions expressed significantly lower levels of HAS2
at each time point compared with cell cultured under conditions promoting dedifferentiation. Furthermore, under both conditions over time, HAS2 expression
was significantly reduced evidenced by greater expression of HAS2 after 1 day
compared with 2 days.
Figure 4.1.2 HAS2 expression is increased in the synthetic phenotype
mRNA expression of HAS2 in hASMCs cultured for 1 or 2 days under conditions
promoting either differentiation or de-differentiation. Data represents mean +
SEM (n≥3), **** = p<0.0001; two-way ANOVA to determine differences in HAS2
expression due to culture media and time. Bonferroni multiple comparisons
examining HAS2 mRNA expression due to culture media at each time point.

42

4.2 Induction of differentiation by serum-deprivation
As seen in Figure 4.1, cells cultured over time in differentiation-promoting
media are induced to express increased levels of differentiation markers with a
significant increase in levels of α-actin and SM22α right from the first day of
culture. As an alternative method of inducing differentiation and examining the
effects of various treatments under conditions without the potential for interaction
with serum-containing components, cells were cultured in de-differentiationpromoting media for 2 days and then deprived of serum over time. Cells were
lysed and harvested daily over a 5-day time period and subsequently analyzed
for protein levels of differentiation markers (α-actin and SM22α) via western
blotting. Cells cultured for 2 days under conditions promoting de-differentiation
which were not exposed to the serum-deprived medium were utilized as controls.
Control cells expressed nearly undetectable levels of α-actin and SM22α
and these levels remain reduced even after introducing serum-free medium to
these cells for 1 day. However, after 2 days in serum-deprived media, the cells
began to express increased levels of α-actin, and this trend was significant after
3 to 5 days of serum-deprivation compared to controls. With SM22α protein
levels, significant increase was observed from the 3rd day in serum deprivation
media up to the 5-day time point. Compared to controls, the increase observed in
α-actin protein levels over time was much greater than with SM22α protein
levels. At the 3 day time point, α-actin levels were about 20-fold greater while
about a 1.5-fold increase was observed with SM22α. By the 5th day in serumdeprivation media, over a 50-fold increase was observed with α-actin, whereas
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only about a 3-fold incrrease was observed
o
w
with SM22α.
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Both α-actin and SM22α are proteins which have been shown in the
literature to be markers of the differentiated state [184-186]. Greater levels of αactin are expressed in mature, differentiated vascular SMCs and this actin
isoform is the predominant marker of differentiation in these cells. Furthermore,
α-actin is the single most abundant protein in the cells, accounting for
approximately 40% of the cell protein population [46]. As shown in Figure 4.1.1A
& B, α-actin mRNA and protein levels were significantly increased at each time
point in hASMCs cultured under conditions promoting differentiation, as
compared to cells under de-differentiation-promoting conditions. This significant
increase was consistent over multiple days of culture, thus suggesting that the
quantitation of α-actin protein expression is an effective method of identifying the
differentiated state in these hASMCs. In addition, the interaction between both
the cell culture media as well as the duration of cell culture both have a
significant effect on the increased expression of α-actin in hASMCs cultured
under conditions promoting differentiation.
SM22α is a 22 kDa protein which serves as an actin-association protein
involved in organization of the vascular SMC cytoskeleton and the regulation of
vascular function [187]. This protein is also a well-established marker of the
differentiated smooth muscle phenotype, as increased levels have been
observed with vascular SMC differentiation [184-186, 188]. In these hASMCs, a
significant increase in SM22α protein levels with differentiation-promoting
conditions was observed, as compared to cells cultured under conditions
promoting de-differentiation. However, this effect was seen only during the first 3
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days of culture (Figure 4.1.1C). Compared with the differentiation-promoting
media, the de-differentiation promoting media, which contained an increased
concentration of serum together with the presence of additional growth factors,
effectively induced de-differentiation of these hASMCs. In contrast, the
contractile phenotype produced by the differentiation media resulted from the
absence of high serum and additional growth factors, together with the presence
of increased levels of heparin [6, 165-168, 174, 176, 177].
Increased confluence of vascular smooth muscle cells in-vitro has been
demonstrated to increase expression of markers of differentiation. There was no
significant difference in SM22α levels between cells cultured under
differentiation- or growth-promoting conditions at the 4 or 5 day time-points.
Furthermore, in cells cultured under conditions promoting de-differentiation
significant increase in the levels of α-actin and SM22α at the 5-day time point ,
was observed compared to 1 day. The tendency of differentiation marker
expression to increase in cells cultured under de-differentiation-promoting
conditions for prolonged time may be as a result of increased cell density and
confluence, thus resulting in the induction of differentiation under these
conditions [189].
Hyaluronic acid (HA) is linear polysaccharide possessing a loose and
highly hydrated matrix which functions in tissue homeostasis and affects the
cellular phenotype. Even though it may be synthesized by 3 main synthases
(HAS1, HAS2 and HAS3), HAS2 is the predominant isoform detected in cultured
human aortic SMCs [31, 190]. HAS2 mRNA expression was measured because
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this isoform is known to be highly expressed in vivo during SMC phenotypic
changes that occur during the development of cardiovascular pathologies
including atherosclerosis, neointimal hyperplasia and abdominal aneurysm
development [74, 182, 183]. At each time point of analysis (Figure 4.1.2), there
was significant increase in HAS2 mRNA expression in cells cultured under dedifferentiation-promoting conditions compared with differentiation–promoting
conditions. Also, an inverse correlation between HAS2 and α-actin mRNA
expression was observed (Figure 4.1.1), where the increase in α-actin was
associated with a decrease in HAS2 expression. Thus, in addition to reduction in
differentiation marker expression, HAS2 was utilized as the primary marker of dedifferentiation in these cells.
As an alternative method of inducing differentiation, cells were cultured in
de-differentiation-promoting media for 2 days and then serum-deprived over time.
Under these conditions of serum-deprivation, a trend toward increased
expression of α-actin and SM22α was observed, and these levels were
significant from the 3-day time point up to the 5-day time point. Even though
levels of both markers increased daily with serum-deprivation, an exponential
increase in α-actin levels was observed over time, with up to a 50-fold increase
after 5-days in serum deprivation media, compared to about a 3-fold increase in
SM22α at the same time point. Therefore, similar to the cells cultured over time in
differentiation-promoting media containing high levels of heparin, the serum
deprivation method of inducing differentiation also determined that the
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quantitation of α-actin expression was more effective than SM22α for identifying
the differentiated phenotype.
In summary, for subsequent experiments, hASMCs were cultured either in
differentiation-promoting media, or under conditions of serum-deprivation to
induce the differentiated phenotype in these cells. In addition, de-differentiationpromoting media was used to induce the de-differentiated phenotype in cultured
hASMCs. The observed increase in these markers of differentiation (α-actin
and/or SM22α) in cultured cells was used to assess differentiation while
decrease in these markers denoted reduced differentiation or de-differentiation.
Furthermore, the significant increase in HAS2 expression was a characteristic of
the synthetic phenotype in vitro. Even though the pattern of differentiation
induction was similar between both differentiation markers, the fold increase in αactin protein expression over time was greater than that observed with SM22α.
Since α-actin expression was consistently expressed in cells cultured under
conditions promoting differentiation, and was exponentially greater than SM22α
expression, α-actin was selected as the primary marker of differentiation in these
hASMCs.

Copyright © Oreoluwa O. Adedoyin 2014
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CHAPTER 5: ANGIOTENSIN II TREATMENT CONTRIBUTES TO REDUCED
DIFFERENTIATION IN HUMAN AORTIC SMOOTH MUSCLE CELLS
Introduction
Vascular smooth muscle cells (SMCs) are crucial components of the
vessel wall which are responsible for maintenance of structural and functional
characteristics such as contraction and relaxation, remodeling and repair, growth
and development within the blood vessel [191]. These functions may be
regulated by local and systemic factors resulting in the promotion of physiological
processes, or mediating pathological mechanisms in the development of vascular
diseases. One of such factors is angiotensin II (AngII), which is a potent,
vasoactive, multifunctional peptide synthesized from its precursor (angiotensin I)
by the angiotensin converting enzyme (ACE).
AngII is a pro-inflammatory mitogenic agent which has been demonstrated
to regulate cell proliferation and apoptosis, influence cell migration and
deposition of extracellular matrix within the vessel wall [191]. In in vitro vascular
SMC culture models, AngII has been demonstrated to induce cell proliferation
and migration, in part, by mediating an increase in mRNA and protein expression
of the inducible cyclooxygenase enzyme (COX-2) [192, 193]. Alternatively, AngII
treatment in vascular SMCs may also contribute to cell proliferation and survival
by promoting release of proinflammatory cytokines such as IL-1β [194], inducing
expression of growth-promoting factors such as IGFR-1 [195, 196] and PDGF-D
[197] or by increasing gene expression of ROS and ET-1 in these cells [198]. All
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these effects have been shown to be mediated by activation of numerous
signaling pathways downstream of the Angiotensin II receptors [191].
Angiotensin II has also been reported to regulate the vascular SMC
phenotype and contribute to vascular remodeling by regulating the expression of
markers of both the contractile and synthetic phenotype, as well as altering the
composition of extracellular matrix components. AT1 receptor activation by AngII
has been demonstrated to induce mRNA expression of α-actin in vascular SMCs
mediated partly by increased myocardin expression and SRF binding to CArG
elements within the SM α-actin promoter [199]. Furthermore, AngII treatment in
quiescent cells increased mRNA and protein expression of calponin also
mediated by AT1 receptor activation [200, 201]. On the other hand, increase in
osteopontin (synthetic marker) has been reported with AngII treatment in aortic
SMCs [202]. Also, enhanced AngII signaling due to increased expression of ACE
in miR-143/145 mutant mice is associated with a phenotypic shift in vascular
SMCs from the contractile to the synthetic state [38]. These contrasting findings
indicate that AngII stimulation is able to induce both differentiation and dedifferentiation in vascular SMCs cultured under different conditions by activating
different downstream signaling pathways.
In animal models of vascular disease, AngII treatment has been observed
to contribute to disease pathology by mediating a phenotypic shift from the
contractile to the synthetic phenotype in vascular SMCs. Medial hypertrophy of
the aorta and coronary arteries in a model of AngII-induced hypertension in rats
has been shown to be associated with increased expression of vascular SMC
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synthetic markers, thus indicating a phenotypic shift to the immature dedifferentiated phenotype [203, 204]. Research findings in our lab utilizing an
AngII-infused mouse model of abdominal aortic aneurysms (AAAs) have
demonstrated that increased expression of COX-2 in vascular smooth muscle
cells within the aneurysmal lesion may contribute to pathogenesis of this disease
[71, 148]. Furthermore, COX-2 may contribute to the formation of AngII-induced
AAAs by altering the differentiated phenotype, because COX-2 inhibition with
celecoxib preserves the differentiated phenotype and limits progression of AAAs
in mice [74]. In addition to COX-2 induction, the inducible microsomal synthase
enzyme (mPGES-1) and prostaglandin E2 have been associated with the
pathogenesis of this disease in the AngII-induced mouse model [128, 205].
These findings suggest that AngII may promote the pathogenesis of AAAs by the
induction of specific products of the prostanoid synthetic pathway.
In humans, aortic SMCs located within the aneurysmal lesion have been
shown to exhibit reduced expression of SMC markers of differentiation compared
to normal aorta [53]. In addition, there is increased expression of COX-2 and
microsomal prostaglandin E2 synthase (mPGES-1), and explant tissue obtained
from human AAA biopsies produce increased levels of prostaglandin E2 (PGE2)
[147, 150, 151]. Due to the potential contribution of AngII to the disease
pathology in humans, clinical studies have proposed that inhibition of AngII
production resulting from treatment with ACE inhibitors may be beneficial in
treating AAAs in humans [206-208].
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Therefore, based on results showing increased expression of COX-2 and
mPGES-1 during development of AAAs [147, 150, 151, 209, 210] as well as
reports associating AngII with alteration of the vascular SMC phenotype [199201], the hypothesis that treatment of vascular SMCs with AngII in vitro will
induce expression of COX-2 and mPGES-1, while reducing differentiation in
these cells was proposed. In order to test this, human aortic smooth muscle cells
(hASMCs) were cultured under different conditions and the cells were treated
with varying concentrations of AngII over time. The effect of AngII treatment on
the cell phenotype was studied by measuring protein levels of the markers of
differentiation, α-actin and/or SM22α. In addition, the expression of COX-2 and
mPGES-1 were also measured in order to examine the potential effect of AngII
treatment on the expression of these.

Results
5.1 Effect on α-actin expression from treatment of differentiated hASMCs
with angiotensin II under conditions promoting differentiation.
Cells cultured under conditions promoting differentiation are induced to
differentiate evidenced by the expression of higher levels α-actin over time (see
Figure 4.1.1). I hypothesized that treatment of hASMCs with AngII under
differentiation-promoting conditions would reverse differentiation by significantly
reducing the expression levels of markers of differentiation in these cells. To
investigate the role of AngII in the modulation of the differentiated SMC
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phenotype, hASMCs were cultured under conditions promoting differentiation for
two days and thus induced to differentiate. The cells were subsequently treated
with 0.1, 0.5, or 1 µM concentrations of AngII for either 1 or 2 days under these
same conditions. Control cells were treated with 0.1% PBS for the same time
period. Cells were lysed, harvested at each time point, and then analyzed for
protein levels of α-actin via western blotting.
Treatment with AngII for 1 day did not result in reduction in levels of αactin (Figure 5.1A). However, at the 2-day time point, a trend toward reduction in
differentiation was observed, demonstrated by lower levels of α-actin in AngII
treated cells compared with controls (Figure 5.1B).
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promote the reduction in α-actin levels in AngII-treated cells compared with
vehicle-treated controls.
Cells were plated for 2 days in differentiation promoting media and then
treated with either 0.1 or 0.5 µM of AngII in growth-promoting media for 1 or 2
days. Control cells were treated with vehicle for the same time period. Cells were
lysed, harvested at each time point, and analyzed for protein levels of α-actin via
western blotting.
The lower concentration of AngII (0.1 µM) trended towards increasing αactin expression whereas the higher concentration (0.5 µM) consistently reduced
α-actin expression in these cells at each time point (Figure 5.2 A & B). Treatment
with 0.1 µM AngII trended toward increase in α-actin levels while 0.5 µM showed
reduction compared with vehicle-treated controls.
Since there was a trend toward reduction in α-actin expression with 0.5
µM AngII treatment, differentiated cells were treated daily with either 0.5 µM or
1.0 µM AngII over a longer time period (1 to 4 days) under de-differentiationpromoting conditions, and the effect on α-actin protein levels was examined via
immunocytochemistry. Treatment for either 1 or 2 days did not result in
significant reduction in α-actin expression (Figure 5.2 C&D). However, by the 3rd
day, significant reduction in α-actin levels was observed with 1.0 µM AngII
treatment. Furthermore, both 0.5 and 1.0 µM AngII treatments resulted in
significant reduction in α-actin protein levels compared to vehicle-treated cells by
the 4th day of treatment (Figure 5.2 E&F).
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Figure 5.2 (continued)
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5.3 Reduced α-actin levels in differentiated hASMCs treated with AngII
under de-differentiation-promoting conditions is associated with increased
mPGES-1 expression but not COX-2 expression
With the observation of a trend toward reduction in α-actin protein levels
when differentiated cells were treated with 0.5 µM AngII under conditions
promoting de-differentiation, protein expression levels of mPGES-1 and COX-2
at this concentration of AngII were subsequently examined. Cells were cultured
under differentiation-promoting conditions and then treated with 0.5 µM AngII
under conditions promoting de-differentiation for either 1 or 2 days. Control cells
were treated with the vehicle (0.1% PBS) for the same time period. At each time
point, cells were lysed and harvested and protein levels of COX-2 and mPGES-1
were examined via western blotting.
Treatment with 0.5 µM AngII did not affect COX-2 expression at either the
1 or 2 day time points. However, at the 2-day time point, there was significant
increase in mPGES-1 protein levels.
In addition, protein levels of α-actin in these cells pursuant to mPGES-1
induction by AngII treatment, was subsequently examined. To do this, cells were
differentiated as above and then treated with 0.5 µM AngII under dedifferentiation-promoting conditions for 3 days. At the 3-day time point, cells were
fixed and analyzed for α-actin protein levels via immunocytochemistry. Significant
decrease in α-actin protein levels was observed in 0.5 µM AngII treated cells
compared with vehicle-treated controls.
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cultured under growth promoting conditions for 2 days and then the media was
changed to serum-free media. AngII treatment was initiated at different time
points during the serum-starvation period.
5.4.1 Effect on α-actin expression from the initiation of AngII treatment at
the beginning of serum-deprivation
After culturing cells in growth promoting media for 2 days, the cell media
was changed to serum-free media. At the 2 day time point in which cell media
was changed to serum-deprived media, 0.5 µM or 1 µM AngII in serum-free
media was added to these cells and incubated for 4 days. Vehicle-treated
controls were incubated in 0.1% PBS in serum-free media. Cells were lysed and
harvested each day over the four days and analyzed for α-actin expression via
western blotting.
AngII treatment of growing cells under serum-deprivation conditions
trended towards increase in α-actin protein levels (Figure 5.4.1). These results
indicated that AngII treatment did not reduce α-actin expression in treated cells at
either time point. Instead, there was an unexpected trend toward increase in αactin expression in the AngII treated cells and this was significant at with 0.5 µM
AngII treatment at the 2 day time point.
Figure 5.4.1 Effect on α-actin expression from the initiation of AngII
treatment at the beginning of serum-deprivation
Densitometry and representative western blots showing protein levels of α-actin
in growing cells treated for (A) 1, (B) 2, (C) 3, or (D) 4 days with 0.5 µM or 1.0 µM
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5.4.2 Effect on α-actin expression from the initiation of AngII treatment after
2 days of serum-deprivation
As observed from preliminary data, after 2 days in serum starved media,
hASMCs begin to commence the process of differentiation by expressing
increasing levels of markers of differentiation (see Figure 4.2). I hypothesized
that AngII treatment of cells at this 2 day time point under these conditions over
time will result in inhibition of differentiation evidenced by significant reduction in
expression levels of markers of differentiation. To test this hypothesis, hASMCs
were cultured under growing conditions for 2 days and then the cell media was
changed to serum-free media for two days. Next, either 0.5 or 1.0 µM of AngII
was added into this cell culture media for between 1 to 3 days. Control wells
were treated with vehicle (0.1% PBS). At each time point, cells were lysed and
harvested for α-actin and SM22α protein levels via western blotting.
Treatment with AngII did not result in significant reduction in α-actin
protein levels at each time point examined. Even though there was a trend
toward decrease in SM22α levels after 1 day of treatment, this reduction however
was not consistent over the 2 or 3 day time points (Figure 5.5.2).
Figure 5.4.2 Effect on α-actin expression from the initiation of AngII
treatment after 2 days of serum-deprivation
Densitometry and representative western blots showing protein levels of (A) αactin, or (B) SM22α in growing cells treated for 1, 2, or 3 days with 0.5 µM or 1.0
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5.4.3 Effect on α-actin expression from the initiation of AngII treatment after
3 days of serum-deprivation
As observed from preliminary data, hASMCs cultured initially under
growth-promoting conditions and then switched to serum-free media are induced
to differentiate during the serum-deprivation over time (See Fig 4.2). At the 3-day
time-point of serum-deprivation, significant increase in the levels of differentiation
markers was observed up till the 5-day time point. I hypothesized that treatment
of cells with AngII at this 3 day time-point over time will reverse differentiation in
these cells evidenced by reduced expression levels of differentiation markers.
To test this hypothesis, hASMCs were cultured under growing conditions
for 2 days and then the cell media was changed to serum-free media for 3 days.
At the 3-day time point, either 0.5 or 1.0 µM of AngII was added into this cell
culture media for 1 or 2 days. Control cells were treated with 0.1% PBS for the
same duration.
The results showed that AngII treatment had no significant effect on the
reduction of differentiation in treated cells compared with vehicle-treated controls
(Figure 5.4.3).

71

Figure
F
5.4.3
3 Effect on α-actin ex
xpression ffrom the in
nitiation off AngII
trreatment after
a
3 days
s of serum-deprivatio
on

Densitometr
D
ry and repre
esentative western
w
blo
ots showing
g protein levvels of (A) α
αactin, or (B) SM22α in growing
g
cells treated ffor 1, or 2 d
days with 0..5 µM or 1.0
0
µM AngII un
nder serum--free condittions. Data representss mean + SE
EM (n=3).
1 day

A.

 -actin protein
n

Percent of control
( -actin/ -tubulin)

150
0

Control
AngII (M)

100
0

50
0

0

0

0.5

1.0

α-actin
α-tubulin

72

Figurre 5.4.3 (co
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certain cardiovascular diseases [212]. AngII signaling through the AT1 receptor
has been shown to contribute to the known physiological effects of AngII in adult
humans [213]. Under physiological conditions, ACE expression in the vasculature
is low [38]. However, signaling due to aberrant activity of AngII within the
vasculature may result in increased cardiac dysfunction and development of
diseases [212, 214].
Various animal models have been used to demonstrate pathological
effects of abnormal AngII signaling within the cardiovascular system. Chronic
AngII infusion in animal models has been shown to increase the luminal diameter
of the aorta, and systolic blood pressure, and induce the formation of aortic
aneurysms in mice [215, 216]. Therefore, clinical studies have proposed that
inhibition of Angiotensin II production by ACE inhibitors may be beneficial in
treating AAAs in humans [206-208].
AngII-induced thoracic or abdominal aortic aneurysm formation in animal
models has also been shown to be associated with the reduced expression of
differentiation markers in the vascular SMCs of the aneurysmal lesion [217].
Research in our lab has also reported increased COX-2 expression, reduced
differentiation marker mRNA expression, and increased expression of a marker
of de-differentiation in SMCs of aneurysmal lesions in AngII-induced AAAs in
mice. The effectiveness of celecoxib (COX-2 inhibitor) in treating this disease
was associated with maintenance of a differentiated phenotype in these cells
[74]. Based on these findings, together with the research showing that
transformation of vascular SMCs from the contractile to the synthetic phenotype
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is associated with an increase in AngII production [218], I proposed that
treatment of hASMCs with AngII would increase expression of COX-2 and
mPGES-1, and reduce differentiation.
To study the AngII effects on the hASMC phenotype in vitro, cells were
induced to differentiate and then treated with AngII at various stages of the
differentiation process, as well as under different culture media conditions.
Treatment of differentiated hASMCs with AngII under conditions promoting
differentiation resulted in a non-significant trend toward a reduction in
differentiation evidenced by reduced levels of α-actin over time (Figure 5.1)
Treatment with AngII under de-differentiation-promoting conditions also
demonstrated a trend toward reduction in differentiation especially at the 0.5 µM
concentration. However, 0.1 µM AngII treatment resulted in a trend toward
increase in α-actin expression at both 1 and 2 day time point. Next, the effect on
α-actin protein levels, of daily treatment of differentiated cells with increased
AngII concentrations over a longer time frame under de-differentiation-promoting
conditions, was investigated via immunocytochemistry. Though there was no
significant difference in α-actin protein levels after the first 2 days of treatment,
treatment with either 0.5 µM or 1.0 µM AngII however resulted in significant
reduction in α-actin expression both at the 3 and 4 day time points (Figure 5.2 E
& F).
Furthermore, the effect of AngII treatment on the expression of mPGES-1
and COX-2 was examined. Treatment with 0.5 µM AngII under conditions
promoting de-differentiation resulted in significant induction of mPGES-1 protein
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levels after treatment for 2 days. There was however no significant increase in
COX-2 expression levels with AngII treatment for either 1 or 2 days AngII (Figure
5.3). These findings were quite unexpected since in vitro SMC culture models
indicate that AngII treatment increases COX-2 expression in vascular SMCs.
The induction of COX-2 expression due to AngII stimulation may be an
early event in cultured vascular SMCs. AngII treatment in rat vascular SMCs was
shown to significantly increase COX-2 mRNA expression after treatment for 1
hour and increase COX-2 protein levels after 4 hours. In this study, at the 24
hour time point, the COX-2 expression had returned to basal states [192]. Also,
Frias et al (2003) observed significant increase in COX-2 levels in rat aortic
smooth muscle cells following a 0.5 to 4 hour incubation with AngII [219].
Similarly, AngII treatment in vascular SMCs induced COX-2 mRNA
accumulation, commenced 30 minutes after stimulation and increased up to 2
hours but had diminished greatly by 6 hours after AngII challenge [78].
Furthermore, these authors observed maximal induction of protein levels of COX2 after 4 hours of stimulation with AngII after which COX-2 protein levels
subsequently reduced over a 48 hour time period. Thus, there may have been no
observable increase in COX-2 expression with AngII treatment in our studies due
to the fact that these cells were analyzed for COX-2 protein levels after much
longer AngII-treatment periods (24 to 48 hours), during which COX-2 expression
had probably returned to basal states. It is probable that harvesting AngII-treated
cells at earlier time points in this study may have demonstrated significant
increase in COX-2 protein in these cells.
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Alternatively, the lack of induction of COX-2 protein may be because in
our studies, cells were treated with AngII under conditions promoting dedifferentiation. This may have resulted in maximal induction of COX-2 such that it
was no longer possible to induce COX-2 production with AngII treatment under
these conditions. The increased presence of serum and growth factors has been
shown to contribute to the expression of COX-2 in cells [220-223]. Since the
induction of COX-2 previously observed in various in vitro models was observed
in confluent quiescent cells SMCs [78, 192] which were stimulated with AngII in
the absence of serum and for shorter periods of time, this major difference in
treatment conditions may have further inhibited induction of COX-2 protein.
It is interesting to note also that significant reduction in α-actin levels did
not occur in differentiated cells treated with AngII under de-differentiatedpromoting conditions for 1 to 3 days (Figure 5.2). Only at the 4-day time point
was there significant reduction in α-actin protein levels in these cells. This
reduction occurred after the significant induction of mPGES-1 expression at the 2
day time point suggesting that the reduction in differentiation marker expression
with AngII treatment may not occur early, but subsequent to the induction of
mPGES-1 levels (Figure 5.3).
The effect of AngII treatment on the induction of differentiation via serumdeprivation was subsequently examined. Serum-deprivation promotes the
differentiated state in vascular SMCs by inducing the expression of markers of
differentiation. Furthermore, serum-deprivation provides a suitable condition in
which we can examine the effect of AngII treatment without the potential for
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interaction with serum-containing components. Regardless of the time point of
AngII administration during the process of serum-deprivation, AngII treatment did
not significantly reduce the expression of protein levels of α-actin or SM22α in
these cells (Figure 5.4). In fact, there was a trend toward increase in the protein
levels of differentiation markers in AngII-treated cells over time. These findings
suggest that AngII may not induce reversal of differentiating cells to the synthetic
phenotype in these hASMCs.
The absence of a suitable mitogenic trigger for the activation of
pathological AngII signaling may be a major factor why there was no significant
decrease in α-actin levels in serum-deprived hASMCs treated with AngII under
the same conditions. AngII treatment under de-differentiation-promoting
conditions introduces a variety of growth factors to the cell media which may
provide the suitable milieu for AngII activity and signaling [212]. Thus, AngII
treatment under conditions of serum-deprivation conditions may not have
significantly reduced the expression of differentiation markers in these cells due
to the absence of these mitogenic cues.
Furthermore, even though AngII treatment in confluent quiescent cells
under conditions of serum-starvation has been shown to induce the expression of
COX-2 in cells, this effect has been associated with the induction of cell
proliferation [78, 192], not differentiation. Since COX-2 protein was not measured
under these conditions, it is difficult to ascertain if COX-2 levels were upregulated
with AngII treatment under these conditions of serum-deprivation. Regardless of
the COX-2 expression profile under these conditions, there was a trend toward
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an increase in differentiation with AngII treatment (Figure 5.4.1). AngII-mediated
increase in differentiation markers has been reported by other investigators. The
increase in α-actin gene transcription, as well as calponin mRNA expression and
protein levels, has been observed previously following treatment of cultured
vascular SMCs with AngII [199-201].
The ability of AngII to regulate the vascular SMC phenotype would depend
on AngII receptor expression in the cells. AT1 receptors are abundantly
expressed in cultured vascular SMCs and activation of this receptor by AngII
mediates the growth-promoting effects. The AT2 receptor however is expressed
in early development and in during vascular injury [201]. Reduced expression of
in AT1 and AT2 receptor was observed in passage-dependent manner with older
passages showing reduced expression of these receptors. Heparin treatment
however recovered expression of these receptors in the later passages and
increased expression of vascular SMC markers of differentiation [168]. Sabri et al
(1997) demonstrated that the reduction of SMC differentiation and elevation of
blood pressure in a mouse model of AngII induced hypertension was due to
activation of the AT1 receptor [203]. Conversely, Yamada et al (1999)
demonstrated that AngII activation of the AT2 receptor enhances differentiation of
aortic SMCs [224]. In these studies, the receptor expression pattern of the AngII
receptor was not examined thus cannot attest to their presence or absence in
hASMCs cultured under different conditions. Therefore, the effectiveness of AngII
treatment under these conditions may have resulted from increased expression
of the AT1 receptor.
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Angiotensin II may also be synthesized endogenously by the vascular
SMCs [225]. Fibronectin is an extracellular matrix glycoprotein which contributes
to vascular SMC migration, growth and phenotypic modulation. Upon phenotypic
switch from the contractile to the synthetic phenotype induced by fibronectin,
vascular and human aortic SMCs have been demonstrated to produce increased
levels of AngII, thus contributing to increased proliferation of SMCs [218, 226].
Furthermore, endogenous AngII synthesis was increased in vascular SMCs
obtained from spontaneously hypertensive rats compared with normotensive
ones, and this increase was associated with increased DNA synthesis,
production of growth factors, and decreased expression of differentiation markers
in these cells [227, 228]. Endogenous concentrations of AngII produced in these
hASMCs cultured under different conditions were not measured, but current
research indicates that endogenous AngII production increases during a shift
from the contractile to the synthetic phenotype in hASMCs [218]. However, the
treatment of differentiated cells with AngII under conditions promoting dedifferentiation may have potentiated the actions of the endogenous AngII or other
factors contributing to reduction in differentiation, thereby resulting in the
observed decrease in α-actin expression (Figure 5.3).
In conclusion, AngII stimulation of differentiated hASMCs in vitro may
promote de-differentiation by the induction of mPGES-1 expression in these
cells. Increased mPGES-1 synthesis results in increased production of
prostaglandin E2 (PGE2) and this is the principal prostanoid secreted in proinflammatory conditions. However, there was considerable variability of response
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observed with AngII treatment in these cells, with AngII acting to either reduce or
increase expression of markers of differentiation under different cell culture and
treatment conditions. Only with treatment of differentiated cells with AngII under
conditions promoting de-differentiation was there a significant reduction in α-actin
levels. Therefore, in order to further investigate the mechanisms responsible for
the reduced differentiation of hASMCs observed with AngII treatment, the
contributions of COX-2, mPGES-1, and PGE2 (products of the prostanoid
synthesis pathway) observed to be upregulated in AAA disease models, were
subsequently examined.
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CHAPTER 6: PHARMACOLOGICAL INHIBITION OF COX-2 by CELECOXIB
PROMOTES DIFFERENTIATION IN HUMAN AORTIC SMOOTH MUSCLE
CELLS
Introduction
The cyclooxygenase (COX) enzymes catalyze the rate-limiting step in the
biosynthesis of prostanoids. Two isoforms of the COX enzyme exist: COX-1,
which is the constitutive enzyme, and COX-2, which is the inducible form. The
COX-1 enzyme is primarily associated with “housekeeping” functions in normal
tissues such as hemostatic, gastric protection, and renal water balance [63, 79].
However, in response to stress, cytokines, growth factor stimulation, and
inflammatory stimuli, COX-2 expression increases [79]. The COX enzymes
convert arachidonic acid first into prostaglandin G2 (PGG2) via oxygenation, and
then to prostaglandin H2 (PGH2) via peroxidase activity. PGH2 is subsequently
converted by tissue specific synthases into different prostanoids including
prostacyclin (PGI2), prostaglandin E2 (PGE2), prostaglandin D2 (PGD2),
thromboxane (TXA2), and prostaglandin F2α (PGF2α) [80, 81]. These prostanoids
exert their actions by activating and signaling through their individual receptors.
Thus, the biological actions of these prostanoids may be modulated at the level
of the cyclooxygenase enzymes, individual synthases or the prostanoid receptors
[84].
Increased expression of the inducible cyclooxygenase enzyme (COX-2)
has been implicated in the pathogenesis of numerous diseases including cancer,
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atherosclerosis, osteoarthritis, and aneurysms [149, 229-233]. More specifically,
during the development of abdominal aortic aneurysms (AAAs), recent research
in animal models, as well as human aneurysmal biopsies, has implicated the
COX-2 enzyme in the pathogenesis of this disease. In AngII-induced mouse
models of AAAs, increased expression of COX-2 is observed in SMCs of the
aortic aneurysmal lesions compared with normal aorta [148, 150]. The, genetic
deletion of this COX-2 enzyme has been demonstrated to significantly reduce the
incidence and severity of this disease in animal models [148]. In addition,
pharmacological inhibition of COX-2 with celecoxib is effective in reducing the
incidence, severity, and progression of this disease in murine models [75, 205].
Similarly, in human biopsy explants from AAA lesions, the increase in COX-2
expression has been observed when compared to normal, uninvolved aorta [147,
149, 234].
Aside from the involvement of COX-2 during development of this disease,
alteration of the vascular SMC phenotype has also been observed in the
developing aneurysm in both human biopsies and animal models of AAAs.
Ailawadi et al (2009) observed significant downregulation of markers of
differentiation in the SMCs of aneurysmal lesions, compared with the uninvolved
aorta both in human biopsy specimens, as well as an animal model of this
disease [53]. In an AngII-induced animal model of AAAs, reduction in
differentiation demonstrated by decreased expression of markers of
differentiation and increased expression of markers of de-differentiation are also
observed in the aneurysmal lesion, compared with normal uninvolved aorta. In
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the AngII-induced AAA mouse model, pharmacological inhibition of the COX-2
enzyme with celecoxib is associated with preservation of the differentiated
vascular SMC phenotype [74]. Therefore, the hypothesis that increased
expression of COX-2 will promote reduced differentiation in hASMCs and that
pharmacological inhibition of COX-2 in vitro will be effective in promoting hASMC
differentiation was proposed.

Results
6.1 Characterization of cyclooxygenase-2 (COX-2) expression in hASMCs
6.1.1 Increased hASMC differentiation over time correlates with decreased
COX-2 expression.
The expression of COX-2 in cultured hASMCs was examined and
correlated with differentiation marker expression both at the mRNA and protein
levels. Cells were cultured under either de-differentiation-promoting (d-DC) or
differentiation-promoting conditions (DC) over a period of 4 days for analysis of
mRNA and for a period of 5 days for protein analysis. Samples were harvested
after every 24 hours and analyzed via real-time PCR for mRNA and western
blotting for protein.
Significant reduction in COX-2 mRNA expression in cells cultured under
differentiation-promoting conditions compared with cells cultured under dedifferentiation-promoting conditions at each time point was observed (Figure
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6.1.1A). A similar result was also observed in the protein levels of COX-2 at each
time point, with cells cultured in de-differentiation-promoting media demonstrating
greater levels of COX-2 compared with cells in differentiation-promoting media
(Figure 6.1.1C). This COX-2 expression was correlated with that of α-actin and
an inverse relationship between both their mRNA expression and protein levels
was observed. Cells cultured under differentiating-promoting conditions
expressed significantly higher levels of α-actin mRNA and protein compared with
COX-2 at each time point (Figure 6.1.1B & C)). These results indicate that COX2 expressing hASMCs show reduced expression of differentiation markers.
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Figure 6.1.1 Increased hASMC differentiation over time correlates with
decreased COX-2 expression.
mRNA expression of (A) COX-2 and (B) α-actin in hASMCs cultured for 1 to 4
days under conditions promoting differentiation or de-differentiation. (C)
Representative western blot showing protein levels of COX-2 and α-actin, and
SM22α, with α-tubulin as loading control, in hASMCs cultured for 1 to 5 days
under conditions promoting differentiation or growth. Data represents mean +
SEM (n≥3), **** = p < 0.0001, unpaired Student’s t test comparing expression
levels between differentiation conditions (DC) and growth conditions (d-DC) at
each individual time point.
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under conditions promoting de-differentiation demonstrated significantly
increased COX-2 expression compared with differentiation-promoting media, the
hypothesis that serum-deprivation would reduce expression of COX-2 while
increasing differentiation in these cells was proposed. The levels of COX-2
protein in serum-deprived cells were examined and then correlated with hASMC
differentiation. To do this, cells were cultured under de-differentiation-promoting
conditions for 2 days and then the media was changed to serum-free media for 5
days. Cells were lysed and harvested daily and subsequently analyzed for
protein levels of COX-2 and the markers of differentiation, α-actin and SM22α,
via western blotting.
Cells cultured for 2 days under de-differentiation-promoting conditions
expressed increased COX-2 protein levels compared with conditions of serumdeprivation. By the first day of serum-deprivation, the COX-2 protein levels were
drastically reduced compared with the control, and the COX-2 protein levels
continually reduced over time till it was undetectable (Figure 6.1.2A). However,
as observed previously (Figure 4.2), serum deprivation resulted in an increase in
α-actin and SM22α protein levels, thus indicating the increased differentiation of
the cells.
The induction of COX-2 expression that occurs in response to dedifferentiation-promoting media in cells that were previously serum deprived was
also examined. The re-stimulation of serum-deprived cells with de-differentiationpromoting media increased COX-2 protein levels for the first 2 days, which then
declined by the third and fourth days (Figure 6.1.2B).
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6.2 Effect of COX-2 inhibition by celecoxib on hASMC phenotypic
modulation.
6.2.1 COX-2 inhibition by celecoxib increases α-actin levels in hASMCs
cultured under differentiation-promoting conditions.
The effect of cyclooxygenase 2 (COX-2) inhibition by celecoxib on the
hASMC phenotype in vitro was investigated. Since hASMC cultured under
conditions promoting either de-differentiation or differentiation do express COX-2,
albeit at varying levels, hASMCs were treated with celecoxib under both
conditions. For treatment with celecoxib under reduced levels of COX-2
expression, cells were cultured under differentiation-promoting conditions. The
cells were cultured for 2 days in differentiation-promoting media, and then treated
with either 2, 5 or 10 µM celecoxib for 1, 2 or 3 days. Non drug-treated controls
were incubated with media containing the vehicle (0.1% DMSO). At each time
point, cells were lysed, harvested and analyzed for α-actin protein levels via
western blotting.
A trend toward increase in α-actin protein levels in the celecoxib-treated
cells compared with untreated controls was observed. Although there was a
trend for increased α-actin expression following treatment with 5 µM celecoxib for
1 or 2 days, the change was not statistically significant (Figure 6.2.1). At the 2
and 3 day time points, cells treated with 10 µM celecoxib showed significantly
increased α-actin levels compared with vehicle-treated controls.
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6.2.2 COX-2 inhibition increases α-actin levels in hASMCs cultured under
conditions promoting de-differentiation.
Upon observing increased levels of α-actin in celecoxib-treated cells under
conditions promoting differentiation, the effect of celecoxib on cells cultured
under de-differentiation-promoting conditions in which higher expression of COX2 was observed was examined. Cells were cultured under de-differentiationpromoting conditions for 2 days and then treated with 2, 5, or 10 µM celecoxib for
either 1 day or 2 days. At each time point, cells were fixed and analyzed for αactin levels via immunocytochemistry.
Significant increase in α-actin levels in cells treated with 2 µM celecoxib at
the 1 day time point was observed (Figure 6.2.2A). However, treatment with
either 5 µM or 10 µM of celecoxib at the 1 day time point did not result in a
statistically significant increase in α-actin expression compared to vehicle-treated
controls. In addition, there were no significant differences in α-actin expression
with any of the treatment concentrations after 2 days of treatment (Figure
6.2.2B).
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Figure 6.2.2 COX-2 inhibition increases α-actin levels in hASMCs cultured
under conditions promoting de-differentiation.
Densitometry quantitation of α-actin expression in differentiated cells treated with
celecoxib under de-differentiation-promoting conditions for (A) 1 day or (B) 2
days. Data represents mean + SEM (n=3), * = p < 0.05; one-way ANOVA and
post hoc analysis with Dunnett’s Multiple Comparison test.

*
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6.2.3 Treatment with celecoxib under serum-deprivation conditions inhibits
the induction of differentiation in hASMCs.
Previous results had shown that increased differentiation observed in
serum-deprived hASMC is associated with reduced expression of COX-2 (Figure
6.1.2A). The increase in differentiation was observed to begin after 2 days of
serum-deprivation and the continued increase correlated with the number of days
the cells were in serum-free media. Since, serum deprivation induces
differentiation in these cells, and reduced COX-2 levels were observed under
these conditions, it was hypothesized that treatment of hASMCs with celecoxib
under conditions of serum-deprivation would inhibit any remaining COX-2 that
was expressed during the progression of differentiation thereby potentiating the
induction of differentiation under these conditions. The effect of COX-2 inhibition
at the beginning of serum-deprivation on the induction of differentiation marker
expression in these cells was examined. Cells were cultured for 2 days in dedifferentiation-promoting media and then treated at the beginning of serumwithdrawal with either 2, 5, or 10 µM of celecoxib for between 1, 2, or 3 days.
Cells were harvested each day and then analyzed for α-actin and SM22α protein
levels via western blotting.
Under conditions of serum deprivation, it was observed that celecoxib
treatment did not enhance differentiation in these cells as there was no
significant increase in either α-actin or SM22α protein levels at any of the time
points examined. In fact, by the third day of celecoxib treatment, there was
significant reduction in the protein levels of both markers of differentiation.
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2 by celecoxib under conditions of serum-re-stimulation will induce differentiation
in hASMCs was proposed. To test this hypothesis, cells were cultured for 2 days
under de-differentiation-promoting conditions, and then quiesced overnight by
serum-deprivation. Next, cells were re-stimulated for 1, 2 or 3 days with dedifferentiation-promoting media containing vehicle, 2, 5, or 10 µM celecoxib.
hASMCs were lysed and harvested at each time point and analyzed for protein
levels of α-actin, SM22α and COX-2 via western blotting.
After one day of celecoxib treatment under re-stimulated conditions, there
was a slight trend toward an increase in α-actin and SM22α protein levels in
celecoxib treated cells, compared with vehicle-treated controls. After 2 days of
treatment, the 5µM celecoxib concentration was significant for SM22α but not αactin expression. COX-2 protein levels however began to trend toward reduction
after 1 day treatment and this decrease was significant at all concentrations by
the 2 day time point. In contrast, treatment with 2, 5, or 10 µM celecoxib for 3
days under conditions of re-stimulation resulted in significant reduction of α-actin
and COX-2 expression at all 3 celecoxib concentrations, and a significant
reduction of SM22α at the 10 µM celecoxib treatment (Figure 6.2.4).
Figure 6.2.4. Inhibition of COX-2 by celecoxib under serum-stimulated
conditions reduces hASMC differentiation over time.
Representative western blot and densitometry quantitation of (A) α-actin and (B)
SM22α in growing cells treated with either 2, 5, or 10 µM of celecoxib under
serum-stimulated conditions for 1 day, 2 days, or 3 days. Data represents mean
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preservation of the differentiated SMC phenotype [74]. In order to characterize
the potential role of COX-2 in regulating vascular SMC differentiation, the
expression of the COX-2 enzyme under different cell culture conditions was
examined and correlated with the expression of markers of hASMC differentiation
(α-actin and/or SM22α). Subsequently, the effects of pharmacological inhibition
of COX-2 by celecoxib on the hASMC phenotype under conditions of increased
or decreased COX-2 expression were investigated.
An inverse correlation between COX-2 and differentiation marker
expression was observed in these cultured hASMCs. Increase in hASMC
differentiation induced either by differentiation-promoting media (Figure 6.1.1) or
serum-deprivation (Figure 6.1.2A) was associated with reduced COX-2
expression. However, COX-2 expression was significantly increased in cells
cultured under growth-promoting conditions, compared to cells cultured under
differentiation-promoting conditions, at each time point (Figure 6.1.1). In addition,
re-stimulation of serum-deprived cells induced expression of COX-2 after serum
deprivation for 1 or 2 days (Figure 6.1.2B). Thus, incubation of hASMCs in media
containing growth-promoting agents including increased serum and growth
factors is associated with the induction of COX-2 mRNA and protein expression.
In addition, based on the differentiation state of these cells, differing levels of
COX-2 expression in these hASMCs was observed regardless of the cell culture
conditions.
Cell stimulation by media containing serum and/or growth factors has
been demonstrated to induce the expression of COX-2 in a variety of cell types
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including vascular SMCs [220-223]. Under growth-promoting conditions, cells are
cultured in media containing increased serum (about 5% FBS) and a variety of
growth factors, thus resulting in increased transcription and translation of COX-2
in these cells compared with cells cultured under differentiation-promoting
conditions. Removal of these stimulants (serum and growth factors) during
serum-deprivation however, resulted in the significant reduction in COX-2
expression, with protein levels measured under this condition becoming greatly
reduced over time. Furthermore, serum and growth factors have been shown to
trigger activation of vascular SMCs to the synthetic phenotype [174]. Conversely,
with the induction of differentiation in serum-deprived cells, significant reduction
in COX-2 protein levels over time was observed.
To further understand the mechanisms by which COX-2 may regulate the
cells phenotype the effects of pharmacological inhibition of COX-2 by celecoxib
on cell differentiation under conditions of increased or decreased COX-2
expression was examined. Celecoxib treatment of differentiating cells further
promoted differentiation in both a time and dose- dependent manner (Figure
6.2.1), whereas with cells cultured under conditions promoting de-differentiation,
celecoxib induced differentiation only at the lowest concentration (Figure 6.2.1).
Since culturing cells under de-differentiation-promoting conditions greatly induces
COX-2 expression, it was expected that a higher treatment concentration of
celecoxib of 10 µM would be required to inhibit COX-2 sufficiently to promote
differentiation, similar to that observed in the differentiated cells. However, it was
surprising to observe that the lowest celecoxib concentration used (2 µM)
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promoted a significant increase in α-actin after treatment for 1 day, whereas, the
highest concentration of 10 µM trended toward a reduction in α-actin levels over
time. The 2 µM celecoxib treatment was proposed to provide more specific
inhibition of COX-2 than either the 5 or 10 µM concentrations under these
conditions thereby resulting in the observed increase in α-actin expression in
these cells.
Previous reports have shown that serum-deprivation over time induces the
expression of differentiation markers in vascular SMCs [23, 173, 174] and our
current findings show that this condition is associated with reduced expression of
COX-2, the levels of which become undetectable over time (Figure 6.1.2). Based
on this finding, it was proposed that since reduced expression of COX-2 is
associated with increased expression of differentiation markers, then inhibition of
COX-2 by celecoxib under these conditions would promote the early induction of
differentiation. At the initiation of serum-deprivation, the expression of COX-2 in
these cells is significantly reduced but there was no significant increase in α-actin
expression until the 3rd day of serum-deprivation (Figure 6.1.2A). In order to
investigate if inhibition of COX-2 will induce differentiation in treated cells before
the 3-day time point, hASMCs were treated with 2, 5 or 10 µM celecoxib under
conditions of serum-deprivation over time. Celecoxib treatment however, did not
induce differentiation marker expression in these cells (Figure 6.2.3). On the
contrary, COX-2 inhibition by celecoxib under conditions of serum-deprivation
over time was observed to reduce expression of α-actin and SM22α and this
reduction was significant by the 3rd day of celecoxib treatment.
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In general, it is expected that cell treatment with pharmacological agents
in conditions of serum-free media provides the opportunity to explore effects of
these agents on hASMC differentiation without the potential for interaction with
constituents in the serum. The observation of de-differentiation in cells treated
with celecoxib under conditions of serum-deprivation is potentially due to multiple
factors. First, celecoxib is a molecule which significantly binds to albumin.
Studies analyzing protein binding in serum have shown that approximately 97%
of celecoxib is bound to albumin [236]. The high level of protein binding in serumcontaining media would be expected to limit the activity of the compound. Thus,
in serum-free media, the activity of celecoxib would be expected to be increased,
thereby lowering the concentration required to effectively inhibit COX-2.
Concentrations of celecoxib that are approximately 10-fold higher than those
required for inhibiting COX-2 are known to inhibit other intracellular targets, the
best characterized being the Akt signaling pathway. In the current studies
utilizing celecoxib treatments in serum-free media, the lack of protein binding
may have allowed sufficient inhibition of targets other than COX-2 and the
observed reduction in expression of differentiation markers. A second potential
mechanism includes the inhibition of COX-1. Similar to the inhibition of Akt,
concentrations of celecoxib that are approximately 10-fold higher than those
required for inhibiting COX-2 result in the inhibition of COX-1. Because individual
prostanoid synthases are coupled differently to either COX-1 or COX-2, the
inhibition of COX-1 by celecoxib could result in reduced production of different
prostanoids than that which results from inhibiting COX-2. It is known that
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prostacyclin affects cellular differentiation in ways that are opposite of the effects
of PGE2. Therefore, effects of celecoxib observed in the current studies may
have also resulted from the inhibition COX-1 resulting in a decrease of
prostacyclin synthesis [33].
Serum-stimulation on the other hand increases COX-2 expression in
vascular SMCs. An increase in COX-2 protein levels in the cells that had been
deprived of serum for overnight and then re-stimulated with serum-containing
growth-promoting media was observed. Even though the increase was sustained
during the first 2 days after re-stimulation, the COX-2 levels gradually began to
reduce from the 3rd day onwards (Figure 6.1.2B). It was proposed that celecoxib
treatment under conditions of increased COX-2 expression would inhibit COX-2
and induce hASMC differentiation in a dose-dependent manner. Though there
was a slight trend toward increase in SM22α protein levels in treated cells
compared with controls after the 2nd day of treatment, this effect was abolished
by the 3rd day with significant reduction in both α-actin and SM22α protein levels
in celecoxib-treated cells. Furthermore, there was significant reduction in the
protein levels of COX-2 at both the 2nd and 3rd day time points in celecoxibtreated cells compared with controls (Figure 6.2.4).
The observation of significant reduction in COX-2 levels with celecoxib
treatment under serum re-stimulated conditions was quite an interesting finding
(Figure 6.2.4). Celecoxib is a COX-2 inhibitor which acts by inhibiting COX-2 and
thus preventing it from converting arachidonic acid to the crucial substrate
(PGH2) which is required for the formation of downstream prostanoids. Even
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though there are numerous research findings demonstrating the COX-2 inhibitory
actions of celecoxib, there is a dearth of research showing selective reduction in
COX-2 expression levels in vascular SMCs by celecoxib treatment. Xu et al
(1999) reported inhibition of COX-2 transcription with reduction in COX-2 mRNA
and protein levels by aspirin and sodium salicylate in a cell-cycle specific manner
[237]. As observed in Figure 6.1.2B, COX-2 protein levels increase when cells
are serum-stimulated following a 24 hour cell quiescence. By the 3rd day after restimulation, levels of COX-2 begin to decrease. The reason for this reduction in
COX-2 levels with celecoxib treatment is not known. One potential mechanism
may result from celecoxib inhibiting the production of a prostanoid that acts to
increase expression of COX-2. One such prostanoid that has been shown to
increase expression of COX-2 is PGE2. Our current studies show that PGE2
synthesis is significantly increased following serum stimulation and this increase
is significantly inhibited by celecoxib treatment. Therefore, the observed
reduction in COX-2 expression following celecoxib treatment may have resulted
from the inhibition of PGE2, thereby limiting the effect of this prostanoid on
inducing COX-2 expression.
A limitation of these findings is the fact that even though there is an
inverse relationship between COX-2 expression and the expression of
differentiation markers, significant increase in differentiation with celecoxib
treatment could not be consistently demonstrated under all the cell culture
conditions studied. In addition, one cannot conclusively attribute the correlation
observed to causation. It is important to note that COX-2 inhibition just like COX112

2 deletion, inhibits the production of prostaglandins formed downstream of this
enzyme. Tang et al (2014) observed that COX-2 deletion in vascular cells in
animal model of atherosclerosis has been shown to reduce levels of
prostaglandins while increasing levels of α-actin in these cells [238]. Therefore,
the increase in differentiation observed with COX-2 inhibition by celecoxib may
be attributable to the inhibition of specific prostanoids downstream of COX-2 that
may be important in decreasing differentiation in these cells.
Moreover, despite the promising findings regarding the effectiveness of COX2 inhibition in treatment of AAAs in animal models, as well as the potential for
celecoxib to promote differentiation or reverse de-differentiation in hASMCs,
treatment of patients suffering from AAA disease with a COX-2 inhibitor may not
be a feasible therapeutic option for treating this disease in humans. This is
because of the increased risk of adverse cardiovascular events associated with
long-term use of certain COX-2 inhibitors [239, 240]. Therefore, to further
understand the mechanisms of COX-2 induced SMC phenotypic modulation, key
mediators of the prostaglandin synthesis pathway downstream of COX-2 which
have been demonstrated to contribute to AAA development were examined as
this could potentially provide new targets for treatment of this disease.
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CHAPTER 7: INHIBITION OF MICROSOMAL PROSTAGLANDIN E
SYNTHASE AND PROSTAGLANDIN E2 PROMOTES DIFFERENTIATION IN
HUMAN AORTIC SMOOTH MUSCLE CELLS
Introduction
Prostaglandin E2 (PGE2) is the principal prostanoid secreted during
inflammation and is involved in production of pro-inflammatory cytokines in a
variety of cells [4, 17, 52, 103-105]. The increased expression of inflammatory
mediators induced by PGE2 may contribute to alteration of vascular SMC
contractile function, increased vascular permeability, dilation and pain [4, 52, 85,
103-105]. PGE2 may be synthesized by conversion of arachidonic acid to the
substrate PGH2 by the rate-limiting cyclooxygenase enzyme (COX) and
subsequent action of the Prostaglandin E2 synthase (PGES). PGES exists in 3
main isoforms: cytosolic (c-PGES), type 1 membrane-associated/microsomal
(mPGES-1) and type-2 membrane associated (mPGES-2) [106, 107]. However,
the majority of the PGE2 formed in response to COX-2 induction is dependent on
mPGES-1 [121, 122].
In cardiovascular diseases such as abdominal aortic aneurysms (AAAs),
certain products of the prostanoid synthetic pathway such as COX-2, mPGES-1
and PGE2 have been implicated in the development of this disease in humans as
well as in animal models of the disease. Recent studies have shown increased
expression of COX-2, mPGES-1, and PGE2 synthesis in AAAs [126,147,149,
150]. Similarly, Wang et al (2008) demonstrated that mPGES-1 deletion in AngII-
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induced AAA mouse models suppressed PGE2 production, and significantly
attenuated the incidence and severity of AAAs [128]. Also, genetic deletion of
COX-2 or pharmacological inhibition of this enzyme in an animal model of this
disease has been shown to reduce the incidence and severity of this disease
[148, 205].
Apart from the involvement of mediators of the prostanoid synthetic
pathway in this disease, reduced differentiation of vascular smooth muscle cells
within the vessel wall has been observed during the development of AAAs.
Recent research from our laboratory has demonstrated an inverse association
between the increase in COX-2 expression within the SMCs of the aneurysmal
lesions and the reduced expression of differentiation markers. In these studies,
selective inhibition of the COX-2 enzyme with celecoxib was observed to
preserve the differentiated phenotype of these cells and significantly attenuate
AAA progression compared with saline controls [74, 75]. Furthermore, in human
aneurysmal lesions, reduced expression of markers of differentiation and induced
expression of de-differentiation markers was observed in the human aortic
smooth muscle cells [53].
The mechanisms by which COX-2 promotes reduced differentiation of
vascular SMCs were investigated by examining prostanoids downstream of the
COX-2 enzyme. Based on the previous results showing the induction of mPGES1 with AngII treatment (Figure 4.3), as well as the promotion of differentiation in
cells treated with celecoxib (Figure 5.1), the hypothesis that COX-2 may
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contribute to reduced differentiation in vascular SMCs by the action of mPGES-1derived PGE2 was proposed.
To understand the mechanisms by which the inducible cyclooxygenase
enzyme (COX-2) contributes to reduced differentiation observed during
development of abdominal aortic aneurysms (AAA), human aortic smooth muscle
cells (hASMCs) as our in vitro cell culture model were utilized to study the effects
of various treatments on modulation of the cell phenotype. hASMCs were
cultured under different conditions and treated with PGE2 exogenously over time.
Furthermore, the contribution of endogenous mPGES-1-derived PGE2 on the cell
phenotype by inhibiting mPGES-1 both pharmacologically (15-dPGJ2) and
genetically (mPGES-1 siRNA) were examined. The concentration PGE2
synthesized under various treatment conditions was measured via enzyme
immune assay while mRNA expression and protein levels of a wide variety of
markers of the differentiated as well as de-differentiated phenotype were
examined by real-time PCR and western blotting, respectively.

Results
7.1 Effect of Prostaglandin E2 on hASMC phenotype
7.1.1 Prostaglandin E2 treatment under differentiation-promoting conditions
reduces differentiation in hASMC
To study the role of PGE2 on the hASMC phenotype, cells were cultured
under differentiation-promoting conditions and treated with PGE2 under
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conditions promoting either differentiation. Cells were plated directly into cell
culture plates in differentiation promoting media for 2 days. At the 2 day timepoint, cells were treated with either 0.2 µM or 1 µM PGE2 under conditions
promoting differentiation. Vehicle-treated controls were treated with 0.1% ethanol
under the same conditions. Protein levels of α-actin were measured via
immunocytochemistry and normalized to cellular DNA detection as determined
by SYBR green detection at each time point.
Treatment of differentiated cells with PGE2 under differentiation-promoting
conditions, resulted in a dose-dependent trend toward reduction in α-actin levels
which was significant with 1 µM treatment at the 1 day time point (Figure 7.1.1A)
but not after 2 days (Figure 7.1.1B).
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Figure 7.1.1 Prostaglandin E2 treatment under differentiation-promoting
conditions reduces α-actin levels in differentiated hASMCs
Immunocytochemistry with fluorescent imaging quantitation showing α–actin
expression in differentiated cells treated with PGE2 under differentiationpromoting conditions for (A) 1 day or (B) 2 days. Data represents mean + SEM
(n=3), * = p < 0.05; one-way ANOVA and post hoc analysis with Dunnett’s
Multiple Comparison test.
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7.1.2 Prostaglandin E2 treatment under de-differentiation-promoting
conditions reduces α-actin levels in differentiated hASMCs
Previously, increased synthesis of mPGES-1 (the major enzyme that
produces PGE2) was observed in differentiated hASMCs treated with AngII under
de-differentiation-promoting conditions (Figure 4.3). Therefore, to study the role
of PGE2 on the phenotype of differentiated cells treated with PGE2 under
conditions promoting growth, cells were cultured under differentiating-promoting
conditions for 2 days and subsequently treated with either 0.2 µM or 1 µM PGE2
in de-differentiation-promoting media for either 1 or 2 days. Vehicle-treated
controls were treated with 0.1% ethanol under the same conditions. At each time
point, cells were lysed, harvested, and analyzed for α-actin protein levels via
western blotting.
The treatment of hASMCs with PGE2 under growth-promoting conditions
for 1 day significantly reduced α-actin levels compared with controls (Figure
7.1.2A). Although there was a trend toward a reduction in α-actin levels with the 1
µM PGE2 concentration after 2 days of treatment, this effect was not statistically
significant (Figure 7.1.2B).
Figure 7.1.2 Prostaglandin E2 treatment under de-differentiation-promoting
conditions reduces α-actin levels in differentiated hASMCs
Densitometry and representative western blot showing protein levels of α-actin in
hASMCs cultured under differentiation-promoting conditions and treated with
PGE2 for either (A) 1 day, or (B) 2 days under conditions promoting de119

differentiatio
on. Data rep
presents me
ean + SEM
M (n≥3), ***** = p < 0.00
001; one-wa
ay
ANOVA
A
and
d post hoc analysis
a
witth Dunnett’ss Multiple C
Comparison
n test.

α-actin
calnexin

150
0

B.
Control
PGE2 ( M)

100
0

50
0

0

0

0.2

1.0

α-actin
calnexin
n

120

7.2 Prostaglandin E2 inhibits the induction of differentiation in hASMCs
To further examine the effects of PGE2 on phenotypic modulation, the role
of PGE2 on the induction of differentiation in these cells was explored. As an
alternative method of inducing differentiation and examining the effects of various
treatments under conditions without the potential for interaction with serumcontaining components, cells were cultured in de-differentiation-promoting media
for 2 days and then deprived of serum over time. Previous findings with serumdeprivation indicated that after 2 days of serum deprivation, the cells began to
differentiate as indicated by a 5-fold increase in SM α-actin, as compared to nonserum-deprived controls (Figure 4.2). After 3 days in serum-free medium, the
cells demonstrated significantly increased levels of both α-actin and SM22α.
7.2.1 Prostaglandin E2 treatment initiated after 2 days of serum-deprivation
reduces α-actin protein levels in hASMCs
Differentiation was induced hASMCs by the serum-deprivation method
and then the cells were treated with either 0.2 µM or 1 µM PGE2 in serum-free
media at the 2 day time point. Cells were treated with PGE2 for between 1 to 3
days and cell lysates were collected at each time point and analyzed by
measuring protein levels of α-actin via western blotting.
In cells deprived of serum for 2 days, significant reduction α-actin protein
levels after treatment with PGE2 at the 1, 2 and 3 day time points was observed
(Figure 7.2.1). Surprisingly, the reduction in α-actin observed with 0.2 µM PGE2
was greater than that observed at the higher concentration of 1 µM. In addition,
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7.2.2 Prostaglandin E2 treatment initiated after 3 days of serum-deprivation,
reduces protein levels of SMC markers of differentiation
In previous experiments, significant induction of markers of differentiation
in serum-deprived hASMCs from the 3 day time point onwards had been
observed. Thus, in order to study the effect of PGE2 treatment on differentiation,
the treatment was commenced at the 3-day time point of serum-deprivation.
Cells were treated with PGE2 for either 1 or 2 days and cell lysates were
collected at each time point and analyzed by measuring protein levels of α-actin
and SM22α via western blotting.
Similar to PGE2 treatment after 2 days of serum-deprivation, treatment
after 3 days resulted in significant reduction of both α-actin and SM22α protein
levels, as compared with vehicle-treated controls. However, at both time points,
there was a greater reduction in SM22α levels than with α-actin levels, indicated
by the increased significant difference between treated and control cells in the
SM22α group, as compared to the α-actin group.
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extent of reduction was observed with mRNA expression of Myosin Heavy Chain
II (Myh11) at both time points. Even though significant reduction in α-actin
expression was observed with 1 day treatment, the expression ceased to be
significant at the 2 day time point, as there was observed an upward trend in αactin expression in PGE2 treated cells.
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Figure 7.2.3 Prostaglandin E2 treatment initiated after 3 days of serumdeprivation reduces mRNA levels of SMC markers of differentiation
mRNA expression of (A) α-actin, (B) Smooth muscle 22α (C) Myosin heavy chain
II (D) Smoothelin in hASMCs following incubation in serum-free media for 3 days
and then treated with PGE2 in serum-free media for 1 or 2 days. Data represents
the mean + SEM (n≥3), * = p < 0.05, *** = p < 0.001; one-way ANOVA (Dunnett’s
Multiple comparison test).
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Figure 7.2.3 (continued)
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Figure 7.2.3 (continued)
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Figure 7.2.3 (continued)

7.2.4 Prostaglandin E2 treatment initiated after 3 days of serum-deprivation
induces mRNA levels of SMC markers of de-differentiation
Since it was observed that PGE2 treatment reduces differentiation marker
expression in hASMCs, the effect of PGE2 treatment on the expression of
markers of de-differentiation was also examined in these cells. Cells were
deprived of serum for 3 days and treated with either 0.2 µM or 1 µM PGE2 over a
2-day time period. mRNA was isolated from cell lysates at each time point, and
examined for the expression of the de-differentiation markers HAS2 and MMP2,
by real-time PCR.
Neither HAS2 nor MMP2 mRNA levels were significantly different between
cells treated with vehicle or PGE2 for 1 day. However, at the 2 day time point, a
dose-dependent significant increase in mRNA expression for both MMP2 and
HAS was observed following PGE2 treatment.
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Figure 7.2.4 Prostaglandin E2 treatment initiated after 3 days of serumdeprivation induces mRNA levels of SMC markers of de-differentiation
mRNA expression of (A) HAS2, and (B) MMP2 in hASMCs serum starved for 3
days and then treated with PGE2 for 1 or 2 days. Data represents the mean +
SEM (n≥3), * = p < 0.05; one-way ANOVA (Dunnett’s Multiple comparison test)
1 day
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Figure 7.2.4 (continued)
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7.3 Inhibition of mPGES-1 promotes hASMC differentiation
7.3.1 Serum-stimulation increases endogenous concentrations of PGE2
In order to further examine the role of PGE2 in hASMC phenotypic
modulation, endogenous production of PGE2 under different cell culture
conditions was assessed. The cells were cultured under conditions of serumdeprivation or serum-stimulation and the levels of PGE2 produced by the cells
were determined.
hASMCs were cultured under growth-promoting conditions for 2 days,
then the media was changed to serum-free media overnight, and then the cells
were re-stimulated with growth promoting media. At the point of re-stimulation,
the control cells were treated with fresh serum-free media, thus leaving these
cells unstimulated. After 1 day, cell culture media was collected and then
analyzed for PGE2 concentrations via enzyme immunoassay.
Significant reduction in PGE2 concentrations in media obtained from cells
maintained in serum-free media, compared with cells stimulated with serumcontaining media was observed (Figure 7.3.1). There was about a 20-fold
increase in PGE2 concentrations produced in cells that were in serum-containing
media compared with cells in serum-free media. Therefore, the method of serumstimulation to increase PGE2 concentrations endogenously was subsequently
used.
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Figure 7.3.1 Serum-stimulation increases endogenous concentrations of
PGE2
Enzyme immunoassay analysis of PGE2 concentrations in culture media obtained
from cells cultured for 1 day under re-stimulated or unstimulated conditions. Data

PGE2 concentration (pg/ml)

represents the mean + SEM (n≥3) **** = p < 0.0001; unpaired Student’s t-test.
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7.3.2 Inhibition of COX-2 or mPGES-1 reduces PGE2 concentrations in
hASMCs
Since it was previously demonstrated that that exogenous addition of
PGE2 to differentiated or serum-deprived cells reduced hASMC differentiation
(see sections 7.1 and 7.2), the effect of endogenously produced PGE2 on the
hASMC phenotype was examined. PGE2 production was stimulated
endogenously by serum-stimulation as shown above (7.3.1), and then treated the
cells with appropriate inhibitors under these conditions.
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Previous results (see Figure 6.1.2A) as well as current literature [220-223]
had shown that COX-2 is activated during re-stimulation with serum, therefore,
the effect of COX-2 inhibition on PGE2 production was initially examined. The
hASMCs were cultured under de-differentiation-promoting conditions for 2 days,
the media was changed to serum-free media overnight, and then the cells were
re-stimulated with de-differentiation-promoting media containing varying
concentrations of celecoxib (0.01 µM, 0.1 µM, and 5 µM) or vehicle. After 1 day,
the cell culture media was collected and then analyzed for PGE2 concentrations
via enzyme immunoassay.
There was a dose-response effect observed with celecoxib treatment
under conditions of re-stimulation. Compared to vehicle-treated controls, the
highest concentration of celecoxib used (5 µM) provided the greatest reduction in
PGE2 observed in these cells (about 800-fold reduction), followed by 0.1 µM
(about 400-fold reduction), and then 0.01 µM (about 50-fold reduction) (Figure
7.3.2A).
Current research indicates that mPGES-1 is generally found to be coexpressed with COX-2 in vivo and in vitro [17, 106, 108, 111, 113-119].
Therefore, the effect of pharmacological inhibition of mPGES-1 on PGE2
concentrations in hASMCs under conditions of re-stimulation was examined.
hASMCs were cultured under de-differentaition-promoting conditions for two
days and then made quiescent by changing to serum-deprived medium for 1 day.
After 1 day of serum-deprivation, cells were treated for 1 day with dedifferentiation-promoting media containing either celecoxib, or 15d-PGJ2
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(mPGES-1 inhibitor). As a positive control, cells were cultured under the same
conditions but replaced with serum-deprived media (unstimulated) containing
0.1% ethyl acetate, while negative control cells were re-stimulated with growthpromoting media (re-stimulated) containing vehicle (0.1% ethyl acetate). Cell
media was collected for measurement of PGE2 concentrations via enzyme
immunoassay analysis (EIA).
Significant increase in PGE2 concentrations in re-stimulated cells was
observed compared with unstimulated cells (Figure 7.3.2B). Treatment of cells
with celecoxib (COX-2 inhibitor) significantly reduced PGE2 levels beyond the
levels observed with unstimulated cells. Compared with the re-stimulated
controls, 15d-PGJ2 also reduced significantly PGE2 concentrations in treated
cells, though not to the extent observed by celecoxib treatment or by serumdeprivation. Overall, compared with re-stimulated controls, celecoxib treatment
had the greatest effect on reducing PGE2 levels with about an 800-fold reduction
observed. Treatment with either 0.1 µM or 1 µM 15d-PGJ2 yielded about a 10fold reduction in PGE2 concentrations compared with re-stimulated controls.
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Figure 7.3.2 Inhibition of COX-2 or mPGES-1 reduces PGE2 concentrations
in hASMCs
Enzyme immunoassay analysis (EIA) of PGE2 concentrations in hASMCs treated
with (A) varying concentrations of celecoxib for 1 day under conditions of restimulation. (B) celecoxib, and varying concentrations of 15d-PGJ2 under
conditions of re-stimulation. Data represents mean + SEM (n = 4), ****= P <
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7.3.3 mPGES-1 inhibition by 15d-PGJ2 increases α-actin protein levels in
hASMCs cultured under serum-deprivation, serum-stimulation, and dedifferentiation-promoting conditions
In order to examine the effect of pharmacological inhibition of mPGES-1
and PGE2 synthesis, cultured cells were treated with an mPGES-1 inhibitor (15dPGJ2) under conditions of serum-deprivation and serum-stimulation. Cells were
serum-deprived for 1 day and then treated with varying concentrations of 15dPGJ2 in either serum-deprived media or de-differentiation-promoting media
(serum stimulation). Control cells were treated with vehicle (0.1% ethyl acetate).
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After 1 day of treatment, cells were fixed and analyzed for α-actin expression via
immunocytochemistry.
Results showed that α-actin levels increased in cells treated with 15dPGJ2 under both conditions. The increase observed with treatment under serumdeprivation conditions was significant compared with vehicle-treated controls.
However, though there was a trend towards increase in α-actin levels with
treatment under conditions of re-stimulation, this effect was not significant. Since
treatment with either 0.1 or 1.0 µM of 15d-PGJ2 did not result in significant
induction of α-actin, differentiated cells were treated with a higher concentration
of 15d-PGJ2 (10 µM), under de-differentiation-promoting conditions for 1 day, and
α-actin expression was examined via immunocytochemistry.
Significant induction in α-actin protein levels in cells treated with 10 µM of
15d-PGJ2 under de-differentiation-promoting conditions was observed compared
with vehicle-treated controls (Figure 7.3.3).

Figure 7.3.3 mPGES-1 inhibition by 15d-PGJ2 increases α-actin protein
levels in hASMCs cultured under serum-deprivation, serum-stimulation,
and de-differentiation-promoting conditions
Immunocytochemistry with fluorescent imaging quantitation showing α–actin
expression in hASMCs treated with 15d-PGJ2 for 1 day under (A) serum-free
conditions and (B) serum-stimulated conditions (C) de-differentiation-promoting
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conditions. Data represents mean ± SEM (n = 4), ***= P < 0.001; unpaired
Student’s t-test for (A) and (C); one-way ANOVA for (B).
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7.3.3.1 Rosiglitazone (PPARɣ agonist) does not increase α-actin protein
levels in hASMCs
In order to ascertain if the increase in α-actin observed with 15d-PGJ2
treatment was due to mPGES-1 inhibition and not by the activation of PPARɣ,
rosiglitazone a PPARɣ agonist, was used to treat the cells and the effect on the
hASMC phenotype was examined. Cultured hASMCs were treated with varying
concentrations of rosiglitazone under conditions promoting differentiation (serumdeprived) or de-differentiation (serum-stimulated) for 1 day and then protein
levels of α-actin were subsequently measured by western blotting. Vehicletreated controls were treated with media containing 0.1% DMSO. After 1 day of
incubation, cells treated with rosiglitazone under serum-deprived conditions were
fixed and analyzed for α-actin expression via immunocytochemistry whereas,
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rosiglitazone-treated cells under conditions promoting de-differentiation were
lysed and harvested for analyses via western blotting.
Results showed that α-actin levels did not increase in cells treated with
Rosiglitazone under either condition. Under conditions of serum-deprivation,
there was significant reduction in α-actin levels upon treatment with both 1 and
10µM Rosiglitazone (Figure 7.3.4A). In addition, under serum-stimulated
conditions, rosiglitazone treatment did not induce any increase in α-actin protein
levels in treated cells (Figure 7.3.4B).
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Figure 7.3.3.1 Rosiglitazone (PPARɣ agonist) does not increase α-actin
protein levels in hASMCs
(A) Immunocytochemistry with fluorescent imaging quantitation showing α–actin
expression in hASMCs treated with Rosiglitazone for 1 day under serumdeprived conditions and (B) Representative western blot with densitometry
quantitation showing α–actin expression in hASMC treated with Rosiglitazone for
1 day under serum-stimulated conditions. Data represents mean ± SEM (n = 4),
***= P < 0.001; one-way ANOVA with Dunnetts post hoc test for (A) and unpaired
Student’s t-test for (B).
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media was replaced with serum-free media for 2 days. After each day of serum
deprivation, cell culture media was collected for PGE2 analysis by enzyme
immune assay while cells were lysed and analyzed for either mRNA or protein
expression.
7.3.4.1 siRNA mediated mPGES-1 knockdown induces mRNA expression of
SMC markers of differentiation after 1 day of serum-deprivation
mPGES-1 siRNA-transfected cells were cultured for 2 days under dedifferentiation-promoting conditions and then serum deprived for 1 day. Cells
were lysed, harvested, and mRNA was isolated after 1 day in serum-free media.
mRNA expression levels of mPGES-1, and a variety of markers of differentiation
(α-actin, SM22α, and smoothelin) was subsequently examined.
Significant reduction in mPGES-1 mRNA expression was observed after 1
day of serum-deprivation and this was associated with a significant increase in
the mRNA expression of α-actin and smoothelin (Figure 7.3.4.1). Although there
was a trend toward an increase in SM22α expression in mPGES-1 siRNA
transfected cells, this effect was not significantly different compared with the
control cells.
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Figure 7.3.4.1 siRNA mediated mPGES-1 knockdown induces mRNA
expression of SMC markers of differentiation after 1 day of serumdeprivation
mRNA expression of (A) mPGES-1, (B) α-actin, (C) SM22α (D) Smoothelin in
hASMCs transfected with mPGES-1 siRNA for 2 days in growth promoting media
and then switched to serum-free media for 1 day. Data represents the mean +
SEM (n≥3), * = p < 0.05, **** = p < 0.0001; unpaired Student’s t-test.
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7.3.4.2 siRNA mediated mPGES-1 knockdown induces mRNA expression of
SMC markers of differentiation after 2 days of serum-deprivation
mPGES-1 siRNA-transfected cells were cultured for 2 days under dedifferentiation-promoting conditions and then serum deprived for 2 days. Cells
were lysed, harvested, and mRNA was isolated after 2 days in serum-free media.
mRNA expression levels of mPGES-1, and a variety of markers of differentiation
(α-actin, SM22α, and smoothelin) was subsequently examined.
There was significant reduction in mPGES-1 mRNA expression after 2
days of serum-deprivation and this was associated with significant increase in the
mRNA expression of α-actin and smoothelin (Figure 7.3.4.2). Similar to the 1 day
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experiment, the increase in SM22α expression in mPGES-1 siRNA transfected
cells was not statistically significant.
Figure 7.3.4.2 siRNA mediated mPGES-1 knockdown induces mRNA
expression of SMC markers of differentiation after 2 days serumdeprivation
mRNA expression of (A) mPGES-1 (B) α-actin, (C) SM22α, and (D) Smoothelin
in hASMCs transfected with mPGES-1 siRNA for 2 days in de-differentiationpromoting media and then switched to serum-free media for 2 days. Data
represents the mean + SEM (n≥3), (n = 2 for mPGES-1), *= p< 0.05, *** = p <
0.001; unpaired Student’s t-test.
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Figure 7.3.4.2 (continued)
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7.3.4.3 siRNA mediated mPGES-1 knock-down increases protein levels of
SMC markers of differentiation after serum-deprivation for 1 day
Protein levels of mPGES-1 and markers of differentiation in cells
transfected with mPGES-1 siRNA and compared these with vehicle-transfected
cells were examined. hASMCs were transfected with mPGES-1 siRNA and
cultured for 2 days in de-differentiation-promoting media. After 2 days of
incubation, the cell media was changed to serum-deprived media and then cells
were lysed, harvested and analyzed by western blotting after 1 day of incubation
in serum-free media.
The treatment of hASMCs with mPGES-1 siRNA resulted in a significant
reduction in mPGES-1 protein levels and this was associated with a significant
increase in protein levels of the differentiation markers, α-actin and SM22α
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7.3.4.4 siRNA-mediated mPGES-1 knock-down increases protein levels of
SMC markers of differentiation after serum-deprivation for 2 days
Protein levels of mPGES-1 and markers of differentiation in cells
transfected with mPGES-1 siRNA were examined and compared these with
vehicle-transfected cells. hASMCs were transfected with mPGES-1 siRNA and
cultured for 2 days in growth promoting media. After 2 days of incubation, the cell
media was changed to serum-deprived media and then cells were lysed,
harvested and analyzed by western blotting after 2 days of incubation in serumfree media.
A trend toward a reduction in mPGES-1 levels was observed though this
was not significant. However, there was a significant increase in protein levels of
both α-actin and SM22α in mPGES-1 siRNA transfected cells (Figure 7.3.4.4).
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7.3.4.5 siRNA-mediated mPGES-1 knockdown reduces mRNA expression of
SMC markers of de-differentiation
With the finding that the knockdown of mPGES-1 increased the
expression of differentiation markers, the effect of mPGES-1 knockdown on the
expression of markers of the de-differentiated phenotype in hASMCs was
examined. HAS2 and MMP-2 are both markers of the synthetic phenotype which
are associated with decreased differentiation of vascular SMCs in certain
cardiovascular diseases [53, 74]. Therefore, mRNA expression of HAS2 and
MMP2 were examined in hASMCs transfected with mPGES-1 siRNA and then
compared with vehicle-transfected cells.
hASMCs were transfected with mPGES-1 siRNA and cultured for 2 days
in growth-promoting media. After 2 days of incubation, the cell media was
changed to serum-deprived media and incubated for 2 days. Cells were lysed,
harvested, and mRNA was isolated for real-time PCR analysis at each after
either 1 or 2 days in serum-deprived media. Significant reduction in both HAS2
and MMP2 mRNA expression levels in the mPGES-1 siRNA-transfected cells
was observed, as compared with vehicle-treated controls (Figure 7.3.4.6).
Figure 7.3.4.5 siRNA-mediated mPGES-1 knockdown reduces mRNA
expression of SMC markers of de-differentiation.
mRNA expression of (A) HAS2, and (B) MMP2 in hASMCs transfected with
mPGES-1 siRNA for 1 or 2 days in growth promoting media and then switched to
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serum-free media. Data represents the mean + SEM (n≥3), **= p< 0.01, ***= p<
0.001; unpaired Student’s t-test.
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7.4 PGE2 regulates COX-2 expression in hASMCs
7.4.1 PGE2 treatment increases COX-2 expression under serum-deprivation
conditions
The presence of a feedback loop between PGE2 and COX-2 in which
increased synthesis of PGE2 either promotes induction of COX-2 expression
(positive feedback) [124, 125, 241] or reduces COX-2 expression (negative
feedback) [242-244] has been demonstrated in a variety of cell types. Due to
these different reports regarding the regulation of COX-2 expression by PGE2,
the expression levels of COX-2 in these hASMCs both after treatment with PGE2
exogenously, and after mPGES-1 siRNA-mediated knock down were examined.
Cells were cultured under de-differentiation-promoting conditions for 2 days and
then deprived of serum for 3 days. At this point, 1 µL of either 0.2 mM or 1.0 mM
of PGE2 was added to the media for 1 or 2 days after which mRNA was isolated
from the cells and then analyzed for COX-2 expression via real-time PCR.
At each time point, there was significant increase in COX-2 mRNA
expression with PGE2 treatment compared with untreated controls (Figure 7.4.1).
At the 2-day time point, there was about a 5-fold increase in COX-2 mRNA
expression levels in cells treated with 1 µM PGE2 compared with the vehicletreated control.

163

Figure 7.4.1 PGE2 treatment increases COX-2 expression under serumdeprivation conditions
mRNA expression of COX-2 in hASMCs serum starved for 3 days and then
treated with PGE2 for (A) 1 day or (B) 2 days. Data represents the mean + SEM
(n=3), **= p< 0.01; one-way ANOVA (Dunnetts Multiple comparison test)
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7.4.2 mPGES-1 mediated siRNA knock-down reduces COX-2 expression
under serum-deprivation conditions over time
Since exogenous PGE2 treatment induced COX-2 mRNA expression in
treated cells (7.4.1), the effect of endogenous loss of PGE2 on the expression of
COX-2 in these hASMCs was examined. Cells were cultured directly in dedifferentiation-promoting media containing mPGES-1 siRNA for 2 days and then
the culture media was changed to serum-free media for 1 to 2 days. At each time
point, cells were harvested and mRNA was isolated for analysis by real-time
PCR. In cells treated with mPGES-1 siRNA, significant reduction in COX-2
mRNA expression compared with vehicle-transfected controls was observed at
each time point (Figure 7.4.2).
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Figure 7.4.2 mPGES-1 mediated siRNA knock-down reduces COX-2
expression under serum-deprivation conditions over time
mRNA expression of COX-2 in hASMCs transfected with mPGES-1 siRNA for 2
days in growth promoting media and then switched to serum-free media for (A) 1
day or (2) 2 days. Data represents the mean + SEM (n≥3), *= p< 0.05, *** = p <
0.001; unpaired Student’s t-test.
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7.5 PGE2 treatment reduces mPGES-1 expression in hASMCs
mPGES-1 has been reported to be co-expressed and functionally coupled
with COX-2 in response to a range of extracellular and intracellular stimuli [17,
106, 108, 111, 113, 117-120]. However, other investigators have demonstrated
that mPGES-1 and COX-2 are neither co-expressed nor functionally coupled [79,
245, 246]. Therefore, upon observing the increase in COX-2 mRNA with PGE2
treatment and the decrease in COX-2 expression in cells transfected with
mPGES-1 siRNA, the expression of mPGES-1 in PGE2-treated cells was
examined in order to determine if the expression patterns between both enzymes
would be similar. Cultured hASMCs were serum-deprived for 3 days and then
treated with PGE2 for either 1 or 2 days. Cells were harvested and mRNA was
isolated and analyzed for mPGES-1 expression via real-time PCR. PGE2 treated
cells did not increase mPGES-1 levels as observed with COX-2 treatment in
Figure 7.4.1. On the contrary, significant reduction in mPGES-1 mRNA levels
were observed with PGE2 treatment at both time points (Figure 7.5.1).
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Figure 7.5 PGE2 treatment reduces mPGES-1 mRNA expression in hASMCs
mRNA expression of mPGES-1 in hASMCs serum deprived for 3 days and then
treated with PGE2 for (A) 1 day and (B) 2 days. Data represents the mean + SEM
(n≥3), **= p< 0.01, ***= p< 0.001; one-way ANOVA (Dunnetts Multiple
comparison test).
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7.6 Small interfering RNA (siRNA) mediated mPGES-1 knockdown reduces
PGE2 production by hASMCs
The effect of mPGES-1 siRNA-mediated knock-down on the production
and release of PGE2 into the cell culture media at each time point was examined.
hASMCs were transfected with mPGES-1 siRNA according to the manufacturer’s
protocol via the reverse transfection method and plated the cells in dedifferentiation-promoting media for 2 days. Control wells were treated with the
transfection agent in the absence of the siRNA. After 2 days of incubation, the
media was replaced with serum-free media and then collected after either 1 or 2
days. Subsequently, the media was assessed for PGE2 concentration via enzyme
immunoassay analysis.
Following mPGES-1 siRNA transfection, knockdown of mPGES-1 mRNA
resulted in reduced PGE2 concentrations after both days. However, this effect
was significant only at the 2-day time point (Figure 7.6).
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Figure 7.6 siRNA mediated mPGES-1 knock down reduces PGE2
concentrations in hASMCs
Enzyme immunoassay analysis of PGE2 concentrations in cells transfected with
mPGES-1 siRNA for 2 days and then deprived of serum for (A) 1 day, or (B) 2
days. Data represents mean + SEM (n = 4), ***= p < 0.001; unpaired Student’s ttest.
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7.7 Effect of EP4 receptor activation by CAY10580 on hASMC differentiation
PGE2 exerts its actions via a family of G-protein coupled receptors: EP1, EP2,
EP3 and EP4 having unique tissue expression profiles and whose effects are
mediated through different downstream signaling pathways [79, 127-129]. EP4
receptor protein has been shown to be present in AAA lesions of both mice and
human samples, and inhibition of this receptor in mice results in reduction of the
incidence and severity of AAAs [133, 134]. On the contrary, the deletion of the
EP4 receptor on bone-marrow-derived cells has been shown to enhance the
formation of AAAs in AngII-induced mouse models of the disease [247].
Based on the findings implicating EP4 receptor activation in the development
of AAAs, the hypothesis stating that activation of the EP4 receptor will reduce
differentiation of hASMCs was proposed. To test this hypothesis, cells were
treated with CAY10580, which is a potent EP4 receptor agonist. The experiments
were performed under different cell culture conditions and the effect on the
expression of differentiation markers was measured.

7.7.1 EP4 receptor activation by CAY10580 does not promote dedifferentiation in hASMCs cultured under serum-deprivation conditions.
The effect of EP4 receptor activation on the induction of differentiation in
serum-deprived cells was examined. Cultured cells were serum deprived over a
2 day or 3 day time period and then treated with 0.1 µM CAY10580 for 1 to 2
days. At each time point, cells were lysed, harvested and analyzed for α-actin,
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Figure 7.7.2 EP4 receptor activation by CAY10580 reduces α-actin levels in
hASMCs cultured under conditions promoting differentiation
mRNA expression of α-actin in hASMCs treated with CAY10580 under conditions
promoting differentiation for 1 day. Data represents the mean + SEM (n=4), **=
p< 0.01 unpaired Student’s t-test.

**

Discussion
Among the COX-2-derived prostanoids, PGE2 is a major component of the
pro-inflammatory cascade which has been implicated in the pathology of
numerous diseases including cancer, arthritis, atherosclerosis, and aneurysms
[17, 123, 141, 149, 233, 248-250]. Furthermore, mPGES-1, which is the major
PGE2-synthesizing enzyme, has been shown to be co-expressed with COX-2 in
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vitro and in vivo [17, 122, 231, 233]. Since an increase in COX-2 has been

implicated in the reduced expression of differentiation markers during
development of AAAs, and an increase in mPGES-1 and PGE2 has been
detected in aneurysmal lesions compared to normal aorta, the mechanism by
which COX-2 may be inducing de-differentiation was proposed to be via the
action of mPGES-1-derived PGE2 [74, 126, 128, 147-150]. Using an in vitro
model of cultured hASMCs, the role of PGE2 in phenotypic modulation was
investigated by measuring expression of markers of differentiation and dedifferentiation after exogenous PGE2 treatment and the inhibition of mPGES-1derived PGE2. It was proposed that COX-2 may be contributing to reduced
differentiation of the vascular SMCs by increasing production of PGE2.
Cells were cultured under conditions promoting differentiation using
differentiation-promoting media and treated with PGE2 under either dedifferentiation-promoting or differentiation-promoting conditions. With
differentiated hASMCs treated with PGE2 under conditions promoting
differentiation, both a concentration-dependent decrease in α-actin protein levels
and a statistically significant reduction with a 1 µM PGE2 treatment at the 1 day
time point were observed (Figure 7.1.1). Although there was a trend toward
reduction of α-actin protein levels with 1 µM PGE2 at the 2-day time point, the
effect was not statistically significant. This may be due to PGE2 degradation in
the media over time. The treatment of differentiated cells with PGE2 under
conditions promoting de-differentiation for 1 day also significantly decreased αactin protein levels and the effect was more significant than that observed with
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treatment under differentiation-promoting conditions (Figure 7.1.2). Treatment
with PGE2 for 2 days under conditions promoting de-differentiation however, did
not yield significant reduction in α-actin possibly due to degradation of the PGE2
in the media over time. The reduction induced by PGE2 under these conditions
exceeded that observed with differentiation-promoting media possibly due to the
fact that the increased serum and growth factors present in this de-differentiationpromoting media, may reduce differentiation, and thus potentiate the α-actin–
reducing effects of PGE2 under these conditions (Figure 7.1.2). Media containing
increased serum and growth factors have been shown to contribute to reduced
expression of differentiation markers in vascular SMCs (45, 46, 54, 56-58).
Therefore, treating the hASMCs with PGE2 under these conditions may further
potentiate this reduction in differentiation demonstrated by the greater decrease
in α-actin levels in these cells at the 1 day time point.
Since PGE2 was observed to reduce differentiation in hASMCs, the effect
of PGE2 treatment on the induction of differentiation by serum-deprivation was
examined. Vascular SMCs when deprived of serum over time have been shown
to induce differentiation by upregulating the expression of markers of vascular
SMC differentiation [23, 172-174]. This effect was also observed in the current
studies with hASMCs as shown by the increase in α-actin and SM22α (Figure
4.2). hASMCs which were induced to differentiate under conditions of serumdeprivation with PGE2 were treated for either 1 or 2 days in order to determine if
PGE2 would prevent induction of differentiation under these conditions.
Treatment of serum-deprived cells with PGE2 over time beginning either at the 2
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or 3 day time point resulted in significant reduction in both mRNA and protein
levels of differentiation markers. Even though serum-deprivation over time was
expected to induce expression of differentiation markers, PGE2 treatment
inhibited this induction and also reversed differentiation in these cells (See
section 7.2). Although the observed reduction in protein levels of α-actin and
SM22α was significant, the reduction observed with the 0.2 µM treatment of
PGE2 was greater than that observed with the 1 µM treatment. This could be
attributed to off-target effects occurring in cells treated with higher concentration
of PGE2 under serum-starved conditions.
The effect of PGE2 treatment on the expression of markers of dedifferentiation under conditions of serum-deprivation was also examined. The
results showed that PGE2 treatment increases expression of markers of dedifferentiation, although the time required for producing the effect was different
than for the differentiation markers. Although treatment with PGE2 for 1 day did
not increase expression of these markers, treatment for 2 days did result in the
significant induction of mRNA expression of both HAS2 and MMP2 in these cells.
PGE2 has been observed to alter the differentiation state of a variety of
cell types in vitro and in vivo. For example, PGE2 has been shown to induce the
differentiation of myeloid-derived suppressor cells (MDSC) from bone marrow
stem cells thereby promoting proliferation and malignancy of tumor cells in the
pathogenesis of cancer [251]. In addition, PGE2 has been shown to inhibit
expression of differentiation markers in human lung fibroblast cells [252, 253]. In
vascular SMCs, analogues of prostacyclin or PGE2 increase expression of HAS2
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mRNA and the synthesis of hyaluronic acid [34]. In SMCs induced to dedifferentiate following treatment with interleukin-1beta, PGE2 treatment was
shown to enhance actin filament disorganization, although no changes in the
expression of differentiation markers was reported[104]. These findings
demonstrate that in hASMCs, exogenous PGE2 treatment under a variety of
culture conditions promotes a reduction in the expression of multiple markers of
differentiation. Furthermore, PGE2 treatment induces the expression of markers
of the synthetic phenotype thus promoting the de-differentiation of these cells.
The isoprostane 15-deoxy-∆(12,14)-prostaglandin J(2) (15d-PGJ2), is a
commercially available pharmacological agent which has been shown to be a
potent inhibitor of mPGES-1 in vitro [254]. Recent reports have demonstrated
that 15-dPGJ2 inhibits human mPGES-1 both covalently (by modification of
residue C59) and non-covalently (by binding to the PGH2 binding site) at
concentrations of 1.0 µM or less [254, 255]. 15-dPGJ2 has also previously been
described as an endogenous ligand of PPARγ, although this role is controversial
because of the supraphysiological concentrations of 15d-PGJ2 required to
activate this transcription factor. In vascular SMCs, the concentration of 15dPGJ2 required to increase expression of differentiation markers has been shown
to be 10 µM or greater [95, 97-99, 256]. Therefore, since 15d-PGJ2 is more
potent as an inhibitor of mPGES-1, as compared to an activator of PPARγ, lower
concentrations of 15d-PGJ2 (0.1 µM, 1 µM, 2 µM) were primarily utilized to
determine the effect of pharmacological inhibition of mPGES-1 in preventing
hASMC de-differentiation.
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15d-PGJ2 treatment under conditions of serum-deprivation resulted in
significant increase (approximately 6-fold) in α-actin protein levels compared with
vehicle-treated cells (Figure 7.3.3A). Treatment with 15d-PGJ2 under conditions
of serum-stimulation, significantly reduced PGE2 concentrations (Figure 7.3.2B)
and produced a trend toward an increase in α-actin levels (Figure 7.3.3B). Under
conditions of re-stimulation, the extent of reduction of PGE2 synthesis was similar
between the treatments using both concentrations of 15d-PGJ2 (0.1 µM and 1
µM). The increase in α-actin levels under conditions of serum-deprivation far
exceeded that observed under serum-stimulation. The presence of increased
serum in media under conditions of serum-stimulation may have reduced the
amounts of free 15d-PGJ2 within the cell media available for mPGES-1 inhibition
due to increased protein binding under these conditions. Therefore, to account
for this, cells were treated with 10 µM of 15d-PGJ2 under de-differentiationpromoting media containing increased serum (5% FBS) and after 1 day of
treatment, a 9-fold increase in α-actin expression in treated cells compared with
vehicle-treated controls was observed (Figure 7.3.3C).
To investigate if the effects of 15d-PGJ2 on increasing differentiation is
due to PPARɣ activation and not mPGES-1 inhibition, cells were treated with
Rosiglitazone, a well-established PPARɣ activator under conditions promoting
either differentiation or de-differentiation. Treatment of these cells with
Rosiglitazone did not increase α-actin levels in treated cells like that observed
with 15d-PGJ2 treatment thus suggesting that 15d-PGJ2 is not inducing
differentiation in these cells by acting through PPARɣ (Figure 7.3.3.1).
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Although mPGES-1 is considered a valuable target for developing novel
anti-inflammatory medications, few compounds have been identified with activity
for inhibiting this enzyme. Although 15d-PGJ2 is a potent inhibitor of mPGES-1,
the differentiation-promoting effects observed have the potential to occur through
PPARγ-dependent mechanisms, rather than by inhibiting mPGES-1. Therefore,
as an additional method to the pharmacological inhibition of mPGES-1, PGE2
levels were reduced by transient knockdown of mPGES-1 mRNA expression and
the effect on cell differentiation was examined. Even though PGE2 may be
synthesized by 3 synthases, mPGES-1 was selected for targeting because the
majority of the PGE2 formed in response to COX-2 induction is dependent on this
enzyme [121, 122]. Successful siRNA knock-down of mPGES-1 with consequent
reduction in PGE2 levels has previously been reported in different cell culture
models including vascular SMCs [109, 246, 257]. Furthermore, deletion of
mPGES-1 in vitro and in vivo has been shown to reduce PGE2 levels [107, 127].
Upon siRNA-mediated mPGES-1 transfection, there was significant reduction in
mPGES-1 mRNA expression and protein levels, with concurrent reduction in
PGE2 concentrations. In addition, the reduction in endogenous PGE2 production
was associated with significant increase in mRNA and protein markers of
differentiation, as well as significant reduction in expression of de-differentiation
markers (section 7.3.4). These results are in agreement with results from
pharmacological inhibition of mPGES-1 as well as exogenous PGE2 treatment.
Therefore, these findings have demonstrated that PGE2 is a primary product of
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COX-2 in hASMCs and that activation of the mPGES-1/PGE2 pathway is
prominent mechanism contributing to hASMC de-differentiation.
The expression of COX-2 has long been known to be regulated by
products dependent on COX-2 activity for their synthesis. Feedback mechanisms
have been shown to either increase or decrease COX-2 expression in a variety
of cell types and PGE2 is the prostanoid most often implicated in affecting the
expression of COX-2. In the regulation of cellular differentiation, a positive
feedback mechanism for PGE2 induction of COX-2 functions to suppress the
differentiation of monocytes into dendritic cells [241]. In the kidney of mice, a
negative feedback mechanism occurs in which activation of EP3 receptors by the
PGE2 analog, sulprostone, results in downregulation of COX-2 expression [242].
Similarly in arterial SMCs, the expression of COX-2 is strongly inhibited by
treatment with exogenous PGE2, thereby indicating the presence of a negative
feedback mechanism [243, 244]. In the current studies, the role of PGE2 in
regulating the expression of COX-2 in these cells under different conditions was
examined. Under conditions of serum-deprivation in which low levels of COX-2
are expressed, PGE2 treatment resulted in a dose- and time-dependent increase
in COX-2 mRNA expression (7.4.1). Following the reduction in PGE2 resulting
from siRNA-mediated mPGES-1 knockdown, the opposite effect was observed
with significantly reduced COX-2 expression levels in siRNA-treated cells (7.4.2).
These results indicate the presence of a positive feedback mechanism occurring
with PGE2 increasing COX-2 expression in hASMCs.
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Numerous reports describing the expression characteristics of mPGES-1
have shown the synthase to be co-expressed and functionally coupled with COX2 in response to a range of extracellular and intracellular stimuli [17, 106, 108,
111, 113, 117-120]. Furthermore, the majority of the PGE2 formed in response
these various stimuli which induce COX-2, is dependent on the expression of
mPGES-1 (10, 11, 52). In addition to these findings, other reports describe
differences in expression between COX-2 and mPGES-1. In the murine
mammary gland during lactogenic differentiation, mPGES-1 production of PGE2
is dependent on the activity of COX-1 and not COX-2 [79]. In addition, in rat
microglia cells, LPS-induced mPGES-1 synthesis was not coupled with
corresponding increase in COX-2 levels [245]. Furthermore, in vascular SMCs,
the time-course of IL-1β induced mPGES-1 expression and PGE2 synthesis was
delayed compared with expression of COX-2, and depending on the time of
incubation with IL-1β, either COX-1 or COX-2 could be involved in the synthesis
of PGE2, thus demonstrating uncoupling of mPGES-1 expression with either
COX-2 enzyme [246].
In these studies, profound reduction in PGE2 synthesis in celecoxibtreated cells was observed (7.3.2), as well as a significant increase in PGE2
concentrations when cells were cultured under conditions shown to induce COX2 expression (serum-stimulation) (7.3.1). Therefore, it was expected of both
COX-2 and mPGES-1 to demonstrate coupled expression in hASMCs. In
contrast however, even though PGE2 treatment significantly induced COX-2
mRNA expression, significant reduction in mPGES-1 mRNA expression following
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PGE2 treatment. Therefore, our findings suggest that PGE2 may also promote dedifferentiation by potentiating the actions of COX-2 through a positive feedback
mechanism, and unlike other studies showing similar expression patterns
between COX-2 and mPGES-1, in hASMCs the regulation of expression of these
two enzymes may occur different mechanisms.
PGE2 activity is modulated via activation of four different G-proteincoupled receptors known as EP1, EP2, EP3 and EP4. These four classes of
receptors are structurally and functionally distinct, and their effects are mediated
through different downstream signaling pathways (5, 14, 16, 45, 46). In addition
to the four classes, the EP3 protein exists as 8 different forms that result from
splice variants of the mRNA (86).
In order to investigate the receptors responsible for PGE2's effect on
reducing differentiation, a PGE2 analogue that is a selective agonist of the EP4
receptor was utilized. CAY10580 shows approximately a 100-fold selectivity for
the EP4 receptor over the other EP receptors and has a disassociation constant
for EP4 of approximately 50 nM. To examine the effect of EP4-selective
activation, the initial studies were performed under serum-free conditions to
eliminate the potential for interaction with serum proteins. In order to maintain
selectivity for activating the EP4 receptor, these studies utilized a CAY10580
concentration of 0.1 µM, which is approximately twice the concentration of the
disassociation constant. These studies also examined the effect of different
durations of treatment and at different stages of the serum deprivation used to
induce differentiation. However, neither treatment for 1 day or 2 days under these
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varying conditions significantly reduced the protein expression of α-actin, SM22α
or mPGES-1, as observed following treatment with PGE2 (7.6.1). In addition to
the treatments in serum-free media, the effects of EP4-selective activation under
conditions promoting differentiation was also examined. Because of the presence
of serum in the differentiation-promoting media, a higher concentration of 0.3 µM
of the EP4-selective agonist was utilized. In contrast to our findings using serumfree media, the treatment of hASMCs with the EP4 receptor-selective agonist
significantly reduced expression of α-actin, as determined by
immunohistochemical quantitation (7.6.2). Therefore, although these findings
suggest a role for the EP4 receptor in contributing to reduced differentiation
under differentiation-promoting conditions, a role for this receptor being
responsible for the potent de-differentiation effects of PGE2 on hASMCs that was
observed under multiple culture conditions is not conclusive.
In summary cultured human aortic smooth muscle cells (hASMCs) were
utilized as an in vitro model to explore the role of components of the COX2/mPGES1/PGE2 axis on SMC phenotypic modulation to better understand the
contribution of this to pathway to the alteration in differentiation observed with in
vivo cardiovascular diseases such as AAAs. The reduced differentiation

occurring in hASMCs may be mediated by the action of mPGES-1-derived PGE2.
PGE2 added to the cell media exogenously will reduce differentiation and also
prevent the induction of differentiation in quiescent cells. Furthermore, these
findings demonstrate that inhibition of endogenous production of PGE2 via
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pharmacological or siRNA inactivation of mPGES-1 reduces PGE2 production
and promotes hASMC differentiation.
With the involvement of PGE2 in the pathogenesis of numerous
cardiovascular diseases including AAAs, the inhibition of mPGES-1 is expected
to be an important future method of effectively reducing PGE2 synthesis, thereby
preserving the differentiated phenotype. Therefore, pharmacological inhibition of
mPGES-1 may provide a mechanism of inhibiting PGE2 synthesis that is more
specific than celecoxib treatment, and may serve as a novel target for attenuating
AAA progression by promoting and maintaining a differentiated SMC phenotype.

Copyright © Oreoluwa O. Adedoyin 2014
187

CHAPTER 8: EFFECTS OF OTHER PROSTANOIDS ON HUMAN AORTIC
SMOOTH MUSCLE CELL PHENOTYPIC MODULATION
Introduction
Aside from the effects of PGE2 on the phenotype of vascular smooth
muscle cells (SMCs), other prostanoids have been demonstrated in the literature
to modulate the phenotype of vascular SMCs in a variety of physiological or
pathological disease states. Prostacyclin (PGI2) and thromboxane (TXA2) are
both prostanoids which have been demonstrated to produce opposing effects
within the vasculature. Several studies have indicated that a balance between
these prostanoids is important in the maintenance of the endothelial integrity of
the vessels and overall vascular homeostasis [64, 88, 258].
Prostacyclin is the primary COX-2 product in endothelial cells and the
synthase downstream of COX-2 responsible for PGI2 production is also
expressed in vascular SMCs and platelets [33]. PGI2 is a potent vasodilator and
an inhibitor of platelet aggregation and thrombus formation [87, 259]. These
effects have been demonstrated to be produced by activation of the prostacyclin
receptor (IP) by PGI2 resulting in cAMP production and stimulation of
downstream signaling cascades [260]. In addition to its role as a potent antiaggregatory [259, 261], anti-proliferative [262-265] and anti-migratory [266, 267]
agent, prostacyclin and prostacyclin-mimetic agents have been also
demonstrated to promote the contractile state by inducing the expression of
markers of the differentiated phenotype in vascular SMCs [33, 92].
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Thromboxane (TXA2) on the other hand is primarily a derivative of COX-1catalyzed arachidonic acid metabolism which is released by activated platelets
[268]. Contrary to PGI2, TXA2 is involved in promotion of platelet aggregation and
vasoconstriction [77]. In addition, TXA2 and stable thromboxane-mimetics
activate the thromboxane receptor (TP), stimulate DNA synthesis, and promote
cell proliferation in vascular SMCs [265, 269, 270]. However, there is limited
literature demonstrating the effects of TXA2 or TP receptor stimulation on
vascular SMC phenotypic modulation.
Therefore, the effects of IP and TP receptor stimulation on the
differentiation state of human aortic smooth muscle cells (hASMCs) were
examined. Using Iloprost, a specific agonist of the IP receptor, the effect of IP
stimulation on hASMC differentiation was examined. For the TP receptor, a TP
receptor agonist, IBOP, as well as 2 antagonists, SQ 29548 and seratrodast, to
perturb the effects of these agents individually on the phenotype of these cells.

Results
8.1 Iloprost, a PGI2 mimetic agent promotes differentiation in hASMCs after
1 day of treatment under de-differentiation-promoting conditions.
To examine the effect of PGI2 on the phenotype of hASMCs, cells were
cultured under conditions promoting differentiation for 2 days and then treated
cells with iloprost under media conditions promoting either de-differentiation or
differentiation for 1 or 2 days. Control cells were treated with vehicle (0.1% ethyl
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acetate) in culture media. Cells were lysed, harvested and analyzed for α-actin
protein expression via western blotting. Treatment of hASMCs with iloprost under
conditions promoting de-differentiation resulted in a significant increase in α-actin
protein levels at the 1 day time-point, as compared with vehicle-treated control,
but not after 2 days of treatment (Figure 8.1A and B). In cells treated with Iloprost
under conditions promoting differentiation, there was not a significant increase in
α-actin protein expression, as compared to vehicle-treated cells (Figure 8.1C).
Figure 8.1 Iloprost, a PGI2 mimetic agent promotes differentiation in
hASMCs after 1 day of treatment under de-differentiation-promoting
conditions.
Representative western blot and densitometry quantitation of α-actin in
differentiated cells treated with 1µM of iloprost under de-differentiation-promoting
conditions for (A) 1 day or (B) 2 days; (C) treatment with 1 µM of iloprost under
differentiation-promoting conditions for 1 day. Data represents mean + SEM (n ≥
3), p < 0.05, unpaired Student’s t-test.
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After treatment of differentiated cells with IBOP under differentiationpromoting conditions at both time points, a trend toward reduction in α-actin
protein levels in treated cells compared with vehicle-treated cells was observed,
but this decrease was not statistically significant (Figure 8.2 A & B). For
differentiated cells treated with 5 µM IBOP under conditions promoting dedifferentiation, there was a reduction in α-actin protein levels at both time points
compared with vehicle-treated controls at the 1 day time point (Figure 8.2 C) and
the reduction was significant at the 2-day time point (Figure 8.2 D).
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time points. Cells were lysed, harvested and examined for α-actin protein levels
via western blotting.
Cells treated for 1 day with either 50 or 300 nM SQ29548 demonstrated only
a trend towards a reduction in actin levels, as compared with vehicle-treated
controls (Figure 8.3A and B). This trend was reversed by the 2-day time point
where there was a trend towards an increase in α-actin levels observed in treated
cells at both concentrations, as compared with vehicle-treated controls (Figure
8.3 C and D). However, neither of these effects was statistically significant.
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and then treated with 1, 10 or 100 µM of seratrodast in differentiation-promoting
media. Control cells were treated with vehicle (0.1% of DMSO) in appropriate
media. After 1 day of incubation, cells were lysed, harvested and then analyzed
for α-actin protein levels by western blotting.
Treatment of cells under conditions promoting de-differentiation or
differentiation did not significantly increase α-actin protein levels. A trend toward
reduction in α-actin levels in cells treated with 100 µM seratrodast in dedifferentiation-promoting media was observed and this reduction was significant
compared with vehicle-treated controls in 100 µM seratrodast-treated cells under
differentiation-promoting conditions.
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to having opposing effects on the vasculature, the synthesis of both prostanoids
is also coupled to different COX isoforms with thromboxane A2 synthesis
primarily coupled with COX-1 in platelets, and that of prostacyclin produced by
endothelial cells resulting from the activity of COX-2 [219, 268, 272, 273]. Based
on this coupling, it has been suggested that the increased risk of adverse
cardiovascular events with the prolonged use of COX-2 inhibitors (such as
celecoxib, rofecoxib and valdecoxib) may be due to the decrease in PGI2
production without affecting TXA2 levels, thereby disrupting the homeostatic
balance between both prostanoids [33, 258]. Thus, the hypothesis was proposed
that prostacyclin may contribute to maintenance of cardiovascular homeostasis
by promoting the differentiated phenotype while TXA2 would promote the dedifferentiated phenotype.
In order to investigate the effects of prostacyclin (PGI2) on the SMC
phenotype, the stable prostacyclin-mimetic iloprost was utilized to treat the cells
under different conditions. Iloprost is a structural analog of prostacyclin (PGI2)
which is more stable than prostacyclin and binds to the human recombinant IP
receptors with a Ki of 11 nM [274]. In addition, iloprost has been approved for
clinical use in the management of pulmonary arterial hypertension. Treatment of
differentiated hASMCs with iloprost for 1 day under conditions promoting dedifferentiation showed a significant increase in α-actin protein levels, as
compared with vehicle-treated controls (Figure 8.1). These results are similar to
those reported by other researchers who have demonstrated that PGI2 mimetics
promote the contractile state by inducing the expression of markers of the
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differentiated phenotype in vascular SMCs [33, 92, 275]. Although the
differentiation-promoting effects of PGI2 on SMCs may be expected to be
beneficial in retarding the in vivo development of cardiovascular disease, the
limited synthesis of PGI2 by vascular SMCs reduces the potential significance of
PGI2 as an endogenous modulator of differentiation in our current culture model.
Thromboxane A2 has been shown to promote proliferation [265, 269, 270]
in vascular SMCs. However, though it was previously assumed that the
processes of proliferation and differentiation were coupled, with reduction in
proliferation being a prerequisite for differentiation, current findings have
demonstrated that these processes are not mutually exclusive [88]. Therefore,
since TXA2 promotes cell proliferation, it is not assumed that this product would
also inhibit vascular SMC differentiation. To investigate the effect of thromboxane
(TXA2) on the SMC phenotype, the effect of TXA2 receptor (TP) activation as well
as antagonism in these cells was examined. IBOP, a TXA2 receptor agonist,
produced an overall non-significant trend toward inducing de-differentiation in
these SMCs by reducing expression of α-actin in differentiated cells under both
conditions of differentiation and growth (Figure 8.2). Thromboxane has been
shown to promote hypertrophy of vascular SMCs by upregulating the synthesis of
basic fibroblast growth factor (FGF) endogenously, thereby inducing SMC
proliferation [276]. A variety of growth factors (including FGF) in cell culture
media have been shown to promote the de-differentiated state in cultured
vascular SMCs [6, 167, 174]. Therefore, TXA2 may promote reduction in hASMC
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differentiation by increasing the expression of growth-promoting factors produced
by the cells.
To further investigate the effects of thromboxane on hASMC phenotype,
the effects of TP receptor antagonists on the expression of SMC differentiation
markers in these hASMCs were examined. SQ29548 is potent TP receptor
antagonist demonstrated to bind to the TP receptor with a ki of about 1.6 nM
[277, 278]. hASMCs were treated with SQ29548 at concentrations exponentially
higher than this (50 nM or 300 nM) in order to account for potential binding of this
antagonist to proteins in the serum of the media. Contrasting effects of SQ 29548
were observed treatment in these cells, with treatment for 1 day showing a trend
toward reduction in α-actin protein levels whereas, at the 2 day time point,
treatment with SQ29548 at 50 and 300 nM produced a non-significant trend
toward an increase in α-actin expression. The current studies also utilized the TP
receptor antagonist, seratrodast. Despite treating cells with varying
concentrations of seratrodast, there was no observed increase in α-actin protein
expression, and the highest concentration of seratrodast (100 µM) decreased
expression, likely the result of non-specific binding. Although TXA2 release has
been reported to be coupled with COX-1 in platelets, recent results have shown
that serum-stimulation increases COX-2 expression and this is associated with
TXA2 release from the vascular SMCs. In vascular SMCs obtained from the type
2 diabetic mouse model (db/db mice), TP receptor antagonism by SQ29548 was
demonstrated to reduce COX-2-dependent vascular smooth muscle hyperreactivity mediated by endogenous TXA2 [279]. Similarly, in another model, IL-1β
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stimulation induced COX-2 expression thereby increasing the production of TXA2
in vascular SMCs [81]. Therefore, although increased synthesis of TXA2 that
results from an induction of COX-2 expression has been shown to occur in other
SMC culture models, these current studies suggest that there is limited
importance for a role of TXA2 as an endogenous regulator of hASMC
differentiation.
Despite a thorough search of the literature, there are no reported studies
indicating the effects of TXA2 receptor activation or antagonism on the vascular
SMC phenotype. This may be due to the fact that most of the focus has been on
the detrimental pro-thrombotic, platelet aggregatory, and vasoconstriction effects
of this prostanoid within the vasculature, since thrombus-formation and
vasoconstriction induced by TXA2 are implicated in the incidence of myocardial
infarction, hypertension, and stroke. Even though there is a trend towards
reduction in differentiation with IBOP treatment in these hASMCs, the
concentrations of IBOP utilized are much greater than the EC50 of IBOP (about 2
nM) reported in the literature and thus may not be physiologically relevant [280].
Therefore, it is difficult to ascertain how much, and to what extent the reduction in
α-actin protein levels may be attributed to the action of IBOP activating the TP
receptor or other off-target effects. Furthermore, studies have reported that
stimulation of COX-2 in vascular SMCs promotes endogenous release of TXA2
[81, 279]. Since the level of this prostanoid was not measured in these studies,
the effect of the presence/absence of endogenous levels of TXA2 in the cells with
respect to modulation of the hASMC phenotype is unknown. Even though there
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was an observed increase in α-actin protein levels in cells treated with the TP
receptor antagonist, SQ29548, this effect was not consistent and treatment with
Seratrodast did not induce differentiation in these cells. Therefore, to better
understand the role of TXA2 in hASMC phenotypic modulation, future studies
would need to examine the endogenous production of this prostanoid as well as
TXA2 synthase expression and their correlation with the differentiation state of
the cell.

Copyright © Oreoluwa O. Adedoyin 2014
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